,PageNo,Text
0,page_1,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'A PHASE 4, MULTI-CENTER, RANDOMIZED,', 'DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF', 'THE IMPACT OF APREMILAST (CC-10004) ON', 'QUALITY OF LIFE, EFFICACY, AND SAFETY IN', 'SUBJECTS WITH MANIFESTATIONS OF PLAQUE', 'PSORIASIS AND IMPAIRED QUALITY OF LIFE', 'EMBRACE', 'PROTOCOL NUMBER:', 'CC-10004-PSOR-020', 'DATE FINAL:', '26 SEP 2018', 'Amendment 1:', '17 JAN 2019', 'Amendment 2:', '01 NOV 2019', 'Amendment 3:', '01 MAY 2020', 'EudraCT NUMBER:', '2018-002850-58', 'NCT Number:', 'NCT03774875', 'IND NUMBER:', '070270', 'SPONSOR NAME / ADDRESS:', 'AMGEN, INC.', 'One Amgen Center Drive', 'Thousand Oaks, CA 91320', 'CONFIDENTIALITY NOTICE', 'This document contains confidential information of Amgen. This document', 'must not be disclosed to anyone other than the site study staff and members of', 'the institutional review board/independent ethics committee/institutional', 'scientific review board or equivalent. The information in this document cannot', 'be used for any purpose other than the evaluation or conduct of the clinical', 'investigation without the prior written consent of Amgen. If you have', 'questions regarding how this document may be used or shared, call the Amgen', 'Medical Information number: 1- - 800-77-AMGEN', 'Confidential and Proprietary', '1', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
1,page_2,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION', 'Contact Information', 'Name:', 'MD', 'Title: Senior Director, Global Development', 'Address: Amgen Inc.', 'One Amgen Center Drive', 'Thousand Oaks, CA 91320', 'Phone:', 'E-mail:', 'Note: Only call Amgen Medical Information, if you are not able to reach the Clinical Research', 'Physician(s) or Medical Monitor or designee for emergency calls.', 'Amgen Medical Information: +1-800-77-AMGEN (1-800-772-6436)', 'Confidential and Proprietary', '2', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
2,page_3,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE', '{See appended electronic signature page)', 'Signature of Celgene Therapeutic Area Head', 'dd mmm yyyy', ', MD', 'Vice President and Head of Immunology & Fibrosis Clinical Development', 'Printed Name of Celgene Therapeutic Area Head and Title', 'By my signature, I indicate I have reviewed this protocol and find its content to be', 'acceptable.', 'NOTE: Signed by Celgene based on Approval from Amgen Therapeutic Head', 'Confidential and Proprietary', '3', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
3,page_4,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE', 'Signature of Site Principal Investigator', 'dd mmm yyyy', 'Printed Name of Site Principal Investigator', 'Institution Name:', 'By my signature, I agree to personally supervise the conduct of this study at my study', 'site and to ensure its conduct is in compliance with the protocol, informed consent,', 'Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from', 'Amgen representatives, the Declaration of Helsinki, International Council for', 'Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations', 'governing the conduct of clinical studies.', 'Confidential and Proprietary', '4', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
4,page_5,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE', 'Signature of Coordinating Principal Investigator', 'dd mmm yyyy', 'Printed Name of Coordinating Principal Investigator', 'Institution Name:', 'By my signature, I agree the protocol has been written to comply with ICH Good', 'Clinical Practices guidelines and agree to offer guidance throughout the study as', 'needed.', 'Confidential and Proprietary', '5', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
5,page_6,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'PROTOCOL SUMMARY', 'Study Title', 'A phase 4, multi-center, randomized, double-blind, placebo-controlled study of the impact of', 'apremilast (CC-10004) on quality of life, efficacy, and safety in subjects with manifestations of', 'plaque psoriasis and impaired quality of life.', 'Indication', 'Psoriasis vulgaris is a chronic inflammatory immunologic disorder which manifests primarily in', 'the skin. It is characterized by sharply demarcated areas of affected skin which appear thickened,', 'red, and scaly. The scalp, elbows, knees, lower back, hands, and feet are commonly affected', 'sites. About 80% of affected patients complain of pruritus (Gottlieb, 1998). The psoriatic', 'appearance of the skin is initiated by an antigen presenting cell (APC) - T-cell interaction', 'leading to the release of multiple inflammatory cytokines (Nestle, 2009). In time, this leads to an', 'increased rate of epidermal proliferation with impaired differentiation of keratinocytes, resulting', 'in a thickened epidermis covered by a thickened, parakeratotic stratum corneum. Dermal', 'capillaries become tortuous and dilated, and there is infiltration of both epidermis and dermis', 'with imunologically active cells (Lowes, 2007).', 'According to a European consensus statement on the definition of treatment goals for patients', 'with plaque psoriasis, mild psoriasis is defined as body surface area (BSA) < 10% and Psoriasis', 'Area Severity Index (PASI) < 10 and Dermatology Life Quality Index (DLQI) 10. However,', 'patients with mild psoriasis, as indicated by the somatic scores, BSA and PASI, may present with', 'disease manifestations not adequately controlled by topical therapy alone which, in addition, may', 'lead to a significantly impaired quality of life. These manifestations can include the following:', 'involvement of visible areas, involvement of major parts of the scalp, involvement of genitals,', 'involvement of palms and/or soles, onycholysis or onychodystrophy of at least two fingernails,', 'pruritus leading to scratching, and presence of single recalcitrant plaques.', 'The presence of any of the previously mentioned manifestations alters the classification of mild', 'psoriasis to moderate to severe psoriasis in need of systemic therapy due to significantly', 'impaired quality of life (Mrowietz, 2011).', 'Objectives', 'Primary Objective', 'To assess the impact of apremilast 30 mg twice daily (BID), compared to placebo,', 'on Health-related Quality of Life (QOL) in subjects with manifestations of plaque', 'psoriasis and impaired quality of life at Week 16', 'Secondary Objectives', 'To assess the efficacy and safety of apremilast 30 mg BID, compared to placebo', 'in subjects with manifestations of plaque psoriasis and impaired quality of life at', 'Week 16', 'To assess the long-term effects of apremilast 30 mg BID, with respect to quality', 'of life, efficacy, and safety at Weeks 32 and 52', 'Confidential and Proprietary', '6', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
6,page_7,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Study Design', 'The study will be conducted in compliance with International Council for Harmonisation (ICH)', 'Good Clinical Practices (GCPs). This is a Phase 4, multi-center, randomized, placebo-controlled,', 'double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects', 'with manifestations of plaque psoriasis and impaired quality of life.', 'Approximately 255 subjects will be randomized 2 (apremilast): 1 (placebo) in approximately 6 to', '10 countries in Western Europe. Subjects will be block-randomized to each of the 5', 'manifestations of plaque psoriasis. If subjects present with multiple manifestations, they will be', 'allocated to the manifestation which is most severe, as determined by the subject. However, all', 'manifestations will be assessed for efficacy at each study visit.', 'After a 5-day titration with apremilast, subjects will receive apremilast 30 mg tablets', 'or matching placebo orally twice daily (BID) for 16 weeks. Subjects randomized to', 'the apremilast treatment group will receive apremilast 30 mg tablets orally twice daily', 'for 52 weeks.', 'Subjects randomized to the placebo treatment group will receive placebo tablets', '(identical in appearance to the apremilast 30 mg tablets) orally twice daily for 16', 'weeks. Beginning at Week 16 and after a 5-day titration with apremilast, subjects', 'initially randomized to placebo will be switched to receive apremilast 30 mg BID for', 'an additional 36 weeks (52 weeks total).', 'The study will consist of 4 phases:', 'Screening Phase - up to 5 weeks (35 days)', 'Double-blind Placebo-controlled Phase - Weeks 0 to 16', 'Subjects will receive treatment with either:', '- Apremilast 30 mg tablets orally BID, or', '- Matched placebo tablets orally BID', 'Apremilast Extension Phase - Weeks 16 through 52', '- All subjects will be switched to (or continue with) apremilast 30 mg BID at', 'Week 16 (after a 5-day titration for subjects initially randomized to placebo). All', 'subjects will maintain this dosing to Week 52.', 'Post-treatment Observational Follow-up Phase', '-', '4-week post-treatment observational follow-up for all subjects who complete the', '52-week study treatment or discontinue from the study treatment early', 'Study Population', 'Adult subjects > 18 years of age with manifestations of plaque psoriasis and impaired quality of', 'life.', 'Length of Study', 'The study is designed as a 52-week study, with a 4-week post-treatment observational follow-up.', 'Visits will be scheduled at screening (no more than 5 weeks prior to randomization), Week 0', 'Confidential and Proprietary', '7', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
7,page_8,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '(baseline/randomization), Weeks 2, 4, 16, 20, 32, 44, and 52. A post-treatment observational', 'follow-up will be conducted by telephone at Week 56 or 4 weeks after subject discontinues from', 'the study treatment.', 'The End of Trial is defined as either the date of the last visit of the last subject to complete the', 'post-treatment follow-up, or the date of receipt of the last data point from the last subject that is', 'required for primary, secondary, and/or exploratory analysis, as pre-specified in the protocol,', 'whichever is the later date.', 'Study Treatments', 'Subjects will be dispensed blister cards with 10, 20, and 30 mg apremilast tablets, or identically', 'appearing placebo, for the dose titration, at the baseline visit (Week 0). The treatment schema for', 'dose titration at Baseline is shown in Appendix P.', 'Starting at Week 16, all subjects will be switched to, or will continue with, apremilast. Subjects', 'originally randomized to placebo at Week 0 will be switched to apremilast at Week 16. Dose', 'titration blister cards will be used for subjects switching from placebo to apremilast; blister cards', 'with dummy titration (dosing at 30 mg BID directly) will be used for subjects originally', 'randomized to apremilast. Beginning with the Week 20 visit, all subjects will receive open label', 'high-density polyethylene (HDPE) bottles of investigational product (IP) tablets. All subjects', 'will maintain this dosing through Week 52.', 'Apremilast tablets will be taken orally twice daily, approximately 12 hours apart, through the last', 'treatment visit.', 'Overview of Key Efficacy Assessments', 'Primary Efficacy Endpoint', 'The primary endpoint will be the proportion of subjects who achieve a > 4-point reduction from', 'baseline in the DLQI in subjects receiving apremilast compared to placebo at Week 16.', 'Secondary Efficacy Enppoints', 'Dermatology Life Quality Index (DLQI)', 'Itch Numeric Rating Scale (NRS)', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', 'Body Surface Area (BSA)', 'Psoriasis Area and Severity Index (PASI)', 'Patient Benefit Index (PBI)', 'European Quality of Life 5-Dimension Questionnaire (EQ-5D)', 'The Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:', 'PSO)', 'Overview of Key Safety Assessments', 'Safety assessments will include:', 'Adverse events (AE)', 'Confidential and Proprietary', '8', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
8,page_9,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Pregnancy tests for females of childbearing potential (FCBP)', 'Vital signs', 'Body weight and waist circumference', 'Clinical laboratory tests', 'Statistical Methods', 'This study will randomize approximately 255 subjects to either apremilast 30 mg BID or placebo', 'in a 2:1 ratio, respectively.', 'Assuming a placebo DLQI Responder proportion of 0.50 at Week 16, a minimum total sample', 'size of 210 subjects (140 allocated to apremilast 30 mg and 70 allocated to placebo) is needed to', 'detect a 0.20 difference in the DLQI Responder proportions between apremilast and placebo with', 'at least 0.807 power using a two-sided test at the 0.05 level of significance. This sample size', 'calculation was determined using the commercial software EaST, Version 6.3. Allowing for an', '18% discontinuation rate prior to Week 16, the sample size was revised from a total of 210', 'subjects to a final sample size of 255.', 'The primary analysis for the primary endpoint at Week 16 will be the Cochran-Mantel-Haensze -', '(CMH) test adjusted for the stratification factor at randomization (ie, the 5 manifestation types).', 'This form of the CMH test will use the sample sizes in each of the strata as weights when', 'estimating the adjusted difference in the treatment proportions, constructing 95% Wald', 'confidence intervals for the difference, and conducting a statistical test of no difference between', 'the treatment proportions (ie, H0: TAPR - TPBO = 0 as the null hypothesis).', 'All reasonable attempts will be made to prevent missing data from occurring in this study,', 'especially at Week 16. However, in the case of missing data at Week 16 a multiple imputation', '(MI) method will be incorporated into the primary analysis. The aim of the multiple imputation', 'approach is to incorporate a representative random sample in place of the missing data such that', 'unbiased estimation and valid statistical inferences (ie, confidence intervals and hypothesis', 'testing) can be made.', 'Confidential and Proprietary', '9', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
9,page_10,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'TABLE OF CONTENTS', 'TITLE PAGE', '1', 'PROTOCOL SUMMARY', '6', '1.', 'INTRODUCTION', '17', '1.1.', 'Disease Background', '17', '1.2.', 'Compound Background', '17', '1.3.', 'Rationale', '18', '1.3.1.', 'Study Rationale and Purpose', '18', '1.3.2.', 'Rationale for the Study Design', '18', '2.', 'STUDY OBJECTIVES AND ENDPOINTS', '20', '3.', 'OVERALL STUDY DESIGN', '23', '3.1.', 'Study Design', '23', '3.2.', 'Study Duration for Subjects', '24', '3.3.', 'End of Trial', '25', '4.', 'STUDY POPULATION', '26', '4.1.', 'Number of Subjects', '26', '4.2.', 'Inclusion Criteria', '26', '4.3.', 'Exclusion Criteria', '27', '5.', 'TABLE OF EVENTS', '29', '6.', 'PROCEDURES', '32', '6.1.', 'Screening Period', '32', '6.2.', 'Treatment Period', '33', '6.2.1.', 'End of Treatment', '34', '6.3.', 'Follow-up Period', '34', '6.3.1.', 'Post-Treatment Observational Follow-up', '34', '6.4.', 'Efficacy Assessments', '34', '6.4.1.', 'The Dermatology Life Quality Index (DLQI)', '34', '6.4.2.', 'Static Physicians Global Assessment (sPGA) of Visible Locations', '35', '6.4.3.', 'Scalp Physician Global Assessment (ScPGA)', '35', '6.4.4.', 'Nail Assessments/Nail Psoriasis Severity Index (NAPSI)', '35', '6.4.5.', 'Modified static Physicians Global Assessment of Genitalia (Modified', 'sPGA-G)', '35', '6.4.6.', 'Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)', '36', 'Confidential and Proprietary', '10', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
10,page_11,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '6.4.7.', 'Itch Numeric Rating Scale (NRS)', '36', '6.4.8.', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', '36', '6.4.9.', 'Body Surface Area (BSA)', '36', '6.4.10.', 'Psoriasis Area Severity Index (PASI)', '36', '6.4.11.', 'Patient Benefit Index (PBI)', '37', '6.4.12.', 'The European Quality of Life 5-Dimension Questionnaire (EQ-5D)', '37', '6.4.13.', 'The Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI: PSO)', '37', '37', '6.4.15.', 'Photography', '37', '6.5.', 'Safety Assessments', '38', '6.5.1.', 'Serum and Urine Pregnancy Tests for Females of Childbearing Potential', '38', '6.5.2.', 'Vital Signs, Weight and Waist Circumference', '38', '6.5.3.', 'Physical Examination', '38', '6.5.4.', 'Psychiatric Evaluation', '39', '6.5.5.', 'Severe Diarrhea, Nausea and Vomiting', '39', '6.5.6.', 'Clinical Laboratory Evaluations', '39', '6.5.7.', 'Tuberculosis', '39', '6.5.8.', 'Adverse Events', '40', '7.', 'DESCRIPTION OF STUDY TREATMENTS', '41', '7.1.', 'Description of Investigational Product(s)', '41', '7.2.', 'Treatment Administration and Schedule', '41', '7.3.', 'Method of Treatment Assignment', '41', '7.4.', 'Packaging and Labeling', '42', '7.5.', 'Investigational Product Accountability and Disposal', '42', '7.6.', 'Investigational Product Compliance', '42', '7.7.', 'Overdose', '43', '8.', 'CONCOMITANT MEDICATIONS AND PROCEDURES', '44', '8.1.', 'Permitted Concomitant Medications and Procedures', '44', '8.2.', 'Concomitant Medications Not Recommended', '44', '8.3.', 'Prohibited Concomitant Medications and Procedures', '44', '8.4.', 'Required Concomitant Medications and Procedures', '45', '9.', 'STATISTICAL CONSIDERATIONS', '46', 'Confidential and Proprietary', '11', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
11,page_12,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '9.1.', 'Overview', '46', '9.2.', 'Study Population Definitions', '46', '9.3.', 'Sample Size and Power Considerations', '46', '9.4.', 'Background and Demographic Characteristics', '47', '9.5.', 'Subject Disposition', '47', '9.6.', 'Efficacy Analysis', '47', '9.6.1.', 'Primary Endpoint', '47', '9.6.2.', 'Secondary and Exploratory Efficacy Endpoints', '48', '9.6.3.', 'Photography', '48', '48', '9.6.5.', 'Multiplicity Adjustment', '49', '9.7.', 'Safety Analysis', '49', '9.8.', 'Interim Analysis', '49', '9.9.', 'Other Topics', '49', '9.9.1.', 'Investigational Product Compliance (Tablets)', '49', '9.9.2.', 'Concomitant Therapy', '50', '9.9.3.', 'Steering Committee', '50', '10.', 'ADVERSE EVENTS', '51', '10.1.', 'Monitoring, Recording and Reporting of Adverse Events', '51', '10.2.', 'Evaluation of Adverse Events', '51', '10.2.1.', 'Seriousness', '51', '10.2.2.', 'Severity / Intensity', '53', '10.2.3.', 'Causality', '53', '10.2.4.', 'Duration', '54', '10.2.5.', 'Action Taken', '54', '10.2.6.', 'Outcome', '54', '10.3.', 'Abnormal Laboratory Values', '54', '10.4.', 'Pregnancy', '55', '10.4.1.', 'Females of Childbearing Potential - Collection of Pregnancy Information', '55', '10.4.2.', 'Male Subject With Partners Who Become Pregnant', '56', '10.4.3.', 'Collection of Lactation Information', '56', '10.5.', 'Reporting of Serious Adverse Events', '56', '10.5.1.', 'Safety Queries', '57', 'Confidential and Proprietary', '12', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
12,page_13,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '10.6.', 'Expedited Reporting of Adverse Events', '57', '11.', 'DISCONTINUATIONS', '59', '11.1.', 'Treatment Discontinuation', '59', '11.2.', 'Study Discontinuation', '59', '12.', 'EMERGENCY PROCEDURES', '61', '12.1.', 'Emergency Contact', '61', '12.2.', 'Emergency Identification of Investigational Products', '61', '13.', 'REGULATORY CONSIDERATIONS', '62', '13.1.', 'Good Clinical Practice', '62', '13.2.', 'Investigator Responsibilities', '62', '13.3.', 'Subject Information and Informed Consent', '63', '13.4.', 'Confidentiality', '63', '13.5.', 'Protocol Amendments', '63', '13.6.', 'Institutional Review Board/Independent Ethics Committee Review and', 'Approval', '64', '13.7.', 'Ongoing Information for Institutional Review Board/Ethics Committee', '64', '13.8.', 'Termination of the Study', '65', '14.', 'DATA HANDLING AND RECORDKEEPING', '66', '14.1.', 'Data/Documents', '66', '14.2.', 'Data Management', '66', '14.3.', 'Record Retention', '66', '15.', 'QUALITY CONTROL AND QUALITY ASSURANCE', '68', '15.1.', 'Study Monitoring and Source Data Verification', '68', '15.2.', 'Audits and Inspections', '68', '15.3.', 'Product Complaint', '68', '15.3.1.', 'How to Report a Product Complaint to Amgen', '69', '16.', 'PUBLICATIONS', '70', '17.', 'REFERENCES', '71', '18.', 'APPENDICES', '72', 'Appendix A: Table of Abbreviations', '72', 'Appendix B: The Dermatology Life Quality Index (DLQI)', '75', 'Appendix C: Static Physicians Global Assessment (sPGA) Of Visible Locations', '77', 'Appendix D: Scalp Physician Global Assessment (ScPGA)', '78', 'Confidential and Proprietary', '13', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
13,page_14,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Appendix E: Nail Psoriasis Severity Index (NAPSI)', '79', 'Appendix F: Modified Static Physicians Global Assessment of Genitalia (Modified', 'sPGA-G)', '80', 'Appendix G: Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)', '81', 'Appendix H: Itch Numeric Rating Scale (NRS)', '82', 'Appendix I: Skin Discomfort/Pain Visual Analog Scale (VAS)', '83', 'Appendix J: Psoriasis Area Severity Index (PASI)', '84', 'Appendix K: Patient Needs Questionnaire (PNQ)', '85', 'Appendix L: Patient Benefit Questionnaire (PBQ)', '86', 'Appendix', 'M:', 'European Quality of Life 5-Dimension Questionnaire (EQ-5D)', '87', 'Appendix N: Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI: PSO)', '90', 'Appendix O: Waist Circumference Measurement & Body Mass Index', '91', 'Appendix P: Treatment Schema for Dose Titration at Baseline', '92', 'Appendix Q: Treatment Schema for Dose Titration at Week 16', '93', 'Appendix R: Titration Blister Card', '94', 'Appendix S: Sample Serious Adverse Event Form', '95', 'Appendix T: Pregnancy Notification Form', '98', 'Appendix U: Lactation Notification Form', '99', 'Confidential and Proprietary', '14', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
14,page_15,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'LIST OF TABLES', 'Table 1:', 'Study Objectives', '20', 'Table 2:', 'Study Endpoints', '20', 'Table 3: Table of Events', '29', 'Table 4:', 'Abbreviations and Specialist Terms', '72', 'Confidential and Proprietary', '15', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
15,page_16,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'LIST OF FIGURES', 'Figure 1:', 'Overall Study Design', '24', 'Confidential and Proprietary', '16', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
16,page_17,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '1.', 'INTRODUCTION', '1.1.', 'Disease Background', 'Psoriasis vulgaris is a chronic inflammatory immunologic disorder which manifests primarily in', 'the skin. It is characterized by sharply demarcated areas of affected skin which appear thickened,', 'red, and scaly. The scalp, elbows, knees, lower back, hands, and feet are commonly affected', 'sites. About 80% of affected patients complain of pruritus (Gottlieb, 1998). The psoriatic', 'appearance of the skin is initiated by an antigen presenting cell (APC) - T-cell interaction', 'leading to the release of multiple inflammatory cytokines (Nestle, 2009). In time, this leads to an', 'increased rate of epidermal proliferation with impaired differentiation of keratinocytes, resulting', 'in a thickened epidermis covered by a thickened, parakeratotic stratum corneum. Dermal', 'capillaries become tortuous and dilated, and there is infiltration of both epidermis and dermis', 'with immunologically active cells (Lowes, 2007).', 'According to a European consensus statement on the definition of treatment goals for patients', 'with plaque psoriasis, mild psoriasis is defined as body surface area (BSA) 10% and Psoriasis', 'Area Severity Index (PASI) 10 and Dermatology Life Quality Index (DLQI) VI 10. However,', 'patients with mild psoriasis, as indicated by the somatic scores, BSA and PASI, may present with', 'disease manifestations not adequately controlled by topical therapy alone which, in addition, may', 'lead to a significantly impaired quality of life. These manifestations can include the following:', 'involvement of visible areas, involvement of major parts of the scalp, involvement of genitals,', 'involvement of palms and/or soles, onycholysis or onychodystrophy of at least two fingernails,', 'pruritus leading to scratching, and presence of single recalcitrant plaques. The presence of any of', 'the previously mentioned manifestations may alter the classification of mild psoriasis to', 'moderate to severe psoriasis in need of systemic therapy due to significantly impaired quality of', 'life (Mrowietz, 2011).', '1.2.', 'Compound Background', 'Apremilast (CC-10004) is a specific phosphodiesterase type 4 (PDE4) inhibitor under', 'development for use in the treatment of inflammatory conditions. PDE4 is one of the major', 'phosphodiesterases expressed in leukocytes. PDE4 inhibition by apremilast elevates cyclic', 'adenosine monophosphate (cAMP) levels in immune cells, which in turn down-regulates the', 'inflammatory response by reducing the expression of pro-inflammatory mediators such as tumor', 'necrosis factor (TNF)-a, interleukin (IL)-23, IL-17, and other inflammatory cytokines, and', 'increasing the production of anti-inflammatory mediators.', 'In completed Phase 3 studies in subjects with moderate to severe plaque psoriasis and active', 'psoriatic arthritis, treatment with apremilast was associated with statistically significant and', 'clinically meaningful improvements in multiple efficacy measures. On the basis of these studies,', 'apremilast (OTEZLA) is approved within Europe for the treatment of moderate to severe chronic', 'plaque psoriasis in patients who failed to respond to or who have a contraindication to, or are', 'intolerant to other systemic therapies including cyclosporine, methotrexate or psoralens and', 'long-wave ultraviolet radiation (PUVA) and alone or in combination with disease-modifying', 'antirheumatic drugs (DMARDs) for the treatment of active psoriatic arthritis in adult patients', 'who have had an inadequate response or who have been intolerant to a prior DMARD.', 'Confidential and Proprietary', '17', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
17,page_18,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Apremilast remains under further clinical development for the treatment of inflammatory/', ""autoimmune disorders including Behçet's disease and ulcerative colitis. Further studies within"", 'the approved indications of plaque psoriasis and psoriatic arthritis are also ongoing.', ""Please refer to the Investigator's Brochure (IB) for detailed information concerning the available"", 'pharmacology, toxicology, drug metabolism, clinical studies, and adverse event profile of the', 'investigational product (IP).', '1.3.', 'Rationale', '1.3.1.', 'Study Rationale and Purpose', 'Psoriasis vulgaris is a chronic inflammatory immunologic disorder which manifests primarily in', 'the skin. It is characterized by sharply demarcated areas of affected skin which appear thickened,', 'red, and scaly. The scalp, elbows, knees, lower back, hands, and feet are commonly affected', 'sites. About 80% of affected patients complain of pruritus (Gottlieb, 1998). The psoriatic', 'appearance of the skin is initiated by an APC - T-cell interaction leading to the release of', 'multiple inflammatory cytokines (Nestle, 2009). In time, this leads to an increased rate of', 'epidermal proliferation with impaired differentiation of keratinocytes, resulting in a thickened', 'epidermis covered by a thickened, parakeratotic stratum corneum. Dermal capillaries become', 'tortuous and dilated, and there is infiltration of both epidermis and dermis with immunologically', 'active cells (Lowes, 2007).', 'According to a European consensus statement on the definition of treatment goals for patients', 'with plaque psoriasis, mild psoriasis is defined as BSA < 10% and PASI < 10 and DLQI < 10.', 'However, many patients may present with BSA 10% and PASI 10 but due to the presence of', 'disease manifestations that are difficult to control with topical therapy alone, may have a', 'significantly impaired quality of life (DLQI > 10). These manifestations can include the', 'following: involvement of visible areas, involvement of major parts of the scalp, involvement of', 'genitals, involvement of palms and/or soles, onycholysis or onychodystrophy of at least two,', 'fingernails, pruritus leading to scratching, and presence of single recalcitrant plaques. The', 'presence of any of the previously mentioned manifestations may alter the classification of mild', 'psoriasis to moderate to severe psoriasis in need of systemic therapy due to significantly', 'impaired quality of life (Mrowietz, 2011).', '1.3.2.', 'Rationale for the Study Design', 'This is a Phase 4, multi-center, randomized, double-blind, placebo-controlled study to assess the', 'impact of apremilast on health-related quality of life, efficacy, and safety in patients with', 'manifestations of plaque psoriasis and impaired quality of life. The primary endpoint in this', 'study is the proportion of subjects who achieve a > 4-point change in the DLQI at Week 16', 'compared to placebo. The study population will be very heterogeneous and consist of subjects', 'with a variety of clinical manifestations of psoriasis, such as scalp, nail, palmoplantar, and', 'genital psoriasis and lesions in visible locations. Common among patients with any of these', 'manifestations is a high impairment in Quality of Life (QOL); therefore, assessing the proportion', 'of subjects who achieve a minimal clinically important difference in the DLQI is clinically', 'meaningful. Although the DLQI is the gold standard QOL assessment in psoriasis and other', 'dermatologic diseases, as a patient-reported outcome, it is often associated with a high placebo', 'Confidential and Proprietary', '18', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
18,page_19,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'response rate. To understand the true impact of apremilast on QOL in patients with', 'manifestations of psoriasis and impaired quality of life, a 16-week placebo-controlled period is', 'necessary. After Week 16, subjects who were randomized to placebo will receive active', 'treatment with apremilast through Week 52.', 'Confidential and Proprietary', '19', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
19,page_20,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '2.', 'STUDY OBJECTIVES AND ENDPOINTS', 'Table 1:', 'Study Objectives', 'Primary Objective', 'The primary objective of the study is to assess the impact of apremilast 30 mg twice daily (BID),', 'compared to placebo, on health-related quality of life (qol) in subjects with manifestations of plaque', 'psoriasis and impaired quality of life at Week 16.', 'Secondary Objective(s)', 'The secondary objectives are:', 'To assess the efficacy and safety of apremilast 30 mg BID, compared to placebo in subjects with', 'manifestations of plaque psoriasis and impaired quality of life at Week 16', 'To assess the long-term effects of apremilast 30 mg BID, with respect to quality of life, efficacy, and', 'safety at Weeks 32 and 52', 'Exploratory Objective(s)', 'The exploratory objectives are:', 'To assess the efficacy of apremilast 30 mg BID, compared to placebo in subgroups of subjects with', 'specific manifestations', 'Table 2:', 'Study Enppoints', 'Endpoint', 'Name', 'Description', 'Timeframe', 'Primary', 'Dermatology Life Quality', 'Proportion of subjects who achieve', 'Weeks 16', 'Index (DLQI)', 'a > 4-point reduction from baseline', 'Secondary', 'DLQI', 'Proportion of subjects who achieve', 'Weeks 32, 52', 'a > 4-point reduction from baseline', 'DLQI', 'Mean change from baseline', 'Weeks 16, 32, 52', 'Itch Numeric Rating Scale', 'Mean change from baseline in Itch', 'Weeks 16,32,52', '(NRS)', 'NRS score', 'Skin Discomfort/Pain Visual', 'Mean change from baseline in skin', 'Weeks 16,32,52', 'Analog Scale (VAS)', 'discomfort/pain VAS', 'Body Surface Area (BSA)', 'Mean percent change in BSA', 'Weeks 16,32,52', 'affected by psoriasis', 'Patient Benefit Index (PBI)', 'Proportion of subjects who achieve', 'Weeks 16,32,52', 'PBI score of >', '1', 'Psoriasis Area Severity Index', 'Proportion of subjects who achieve', 'Weeks 16,32,52', '(PASI)', 'PASI < 3', 'Confidential and Proprietary', '20', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
20,page_21,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Table 2:', 'Study Enppoints (Continued)', 'Endpoint', 'Name', 'Description', 'Timeframe', 'European Quality of Life 5-', 'Mean percent change from', 'Weeks 16, 52', 'Dimension (EQ-5D)', 'baseline in EQ-5D score', 'Work Productivity and', 'Mean change in WPAI domain', 'Weeks 16, 52', 'Activity Impairment', 'scores', 'Questionnaire: Psoriasis', '(WPAI: PSO)', 'Treatment-emergent Adverse', 'Frequency and incidence rate of', 'During double-', 'events', 'any TEAE by SOC, PT, severity,', 'blinded treatment', 'and relationship of adverse events', 'and throughout the', '(AEs) to investigational product', 'duration of the', '(IP).', 'apremilast treatment', 'Clinically significant changes', 'Frequency of clinically', 'During double-', 'in body weight, waist', 'significant changes in body', 'blinded treatment', 'circumference, vital signs,', 'weight, waist circumference, vital', 'and throughout the', 'and/or laboratory findings', 'signs, and/or laboratory findings.', 'duration of the', 'apremilast treatment', 'Exploratory', 'Static Physician Global', 'Proportion of subjects who', 'Weeks 16, 32, 52', 'Assessment (sPGA) of', 'achieve sPGA score of 0 or 1', 'Visible locations', '(among subjects randomized with', 'moderate to severe psoriasis in', 'visible areas, defined as sPGA >', '3, which include the dorsal hand,', 'face, neck, or hairline)', 'Scalp Physician Global', 'Proportion of subjects who', 'Weeks 16, 32, 52', 'Assessment (ScPGA)', 'achieve ScPGA score of 0 or 1', '(among subjects randomized with', 'moderate to severe scalp', 'psoriasis, ScPGA > 3)', 'Nail Psoriasis Severity Index', 'Proportion of subjects who', 'Weeks 16, 32, 52', '(NAPSI)', 'achieve NAPSI score of 0 in the', 'target fingernail (among subjects', 'randomized with presence of nail', 'psoriasis, defined as onycholysis', 'and onychodystrophy in at least 2', 'fingernails)', 'Confidential and Proprietary', '21', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
21,page_22,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Table 2:', 'Study Enppoints (Continued)', 'Endpoint', 'Name', 'Description', 'Timeframe', 'Modified Static Physician', 'Proportion of subjects who achieve', 'Weeks 16, 32, 52', 'Global Assessment-Genitalia', 'modified sPGA-G score of 0 or 1', '(sPGA-G)', '(among subjects randomized with', 'moderate to severe genital', 'psoriasis, modified sPGA-G > 3)', 'Palmoplantar Psoriasis', 'Proportion of subjects who achieve', 'Weeks 16, 32, 52', 'Physician Global Assessment', 'PPPGA score of 0 or 1 (among', '(PPPGA)', 'subjects randomized with', 'moderate to severe palmoplantar', 'psoriasis, PPPGA > 3)', 'Confidential and Proprietary', '22', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
22,page_23,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '3.', 'OVERALL STUDY DESIGN', '3.1.', 'Study Design', 'This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact', 'of apremilast on quality of life, efficacy, and safety in subjects with manifestations of plaque', 'psoriasis and impaired quality of life.', 'Approximately 255 subjects will be randomized 2 (apremilast): 1 (placebo) in approximately 6 to', '10 countries in Western Europe. Subjects will be block-randomized to each of the manifestations', 'of psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis, and psoriasis', 'in visible locations). If subjects present with multiple manifestations, they will be allocated to the', 'manifestation which is most severe, as determined by the subject. However, all manifestations', 'will be assessed for efficacy at each study visit.', 'After a 5-day titration with apremilast, subjects will receive apremilast 30 mg tablets', 'or matching placebo orally twice daily (BID) for 16 weeks. Subjects randomized to', 'the apremilast treatment group will receive apremilast 30 mg tablets orally twice daily', 'for 52 weeks.', 'Subjects randomized to the placebo treatment group will receive placebo tablets', '(identical in appearance to the apremilast 30 mg tablets) orally twice daily for 16', 'weeks. Beginning at Week 16 and after a 5-day titration with apremilast, subjects', 'initially randomized to placebo will be switched to receive apremilast 30 mg BID for', 'an additional 36 weeks (52 weeks total).', 'The study will consist of 4 phases:', 'Screening Phase - up to 5 weeks (35 days)', 'Double-blind Placebo-controlled Phase - Weeks 0 to 16', 'Subjects will receive treatment with either', '- apremilast 30 mg tablets orally BID, or', '- matched placebo tablets orally BID', 'Apremilast Extension Phase - Weeks 16 through 52', '- All subjects will be switched to (or continue with) apremilast 30 mg BID at', 'Week 16 (after a 5-day titration for subjects initially randomized to placebo). All', 'subjects will maintain this dosing through Week 52.', 'Post-treatment Observational Follow-up Phase', '-', '4-week post-treatment observational follow-up phase for all subjects who', 'complete the study on treatment or discontinue from the study treatment early', 'After all subjects complete the Week 16 Visit (or discontinue prematurely from the study),', 'selected members of the Amgen study team and external partner who do not have direct', 'interaction with subjects will be unblinded for the analysis of the Week 16 data. These persons', 'may include but are not limited to the following: Therapeutic Area Head, Study lead, Medical', 'Confidential and Proprietary', '23', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
23,page_24,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Director and the Statistician. The results from these analyses may be published prior to the end', 'of the study.', 'The blind should be maintained for persons responsible for the ongoing conduct of the study.', 'Subjects, Investigators and persons responsible for the ongoing conduct of the study will', 'continue to be blinded to the original treatment assignment until the end of the study. These', 'persons are those individuals who have direct interaction with subjects and/or subject', 'assessments, and may include but are not limited to the following: Clinical Trial Manager, Data', 'Manager, Clinical Research Associates (Amgen and External Partners) and Site Monitors.', 'The study will be conducted in compliance with the International Council for Harmonisation', '(ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good', 'Clinical Practice (GCP) and applicable regulatory requirements.', 'Figure 1:', 'Overall Study Design', '-5 0 2 4 16 20 32 44 52 56 Weeks', 'Apremilast 30 MG BID', 'n=255', 'At Week 16 placebo subjects', '(2:1)', 'receive Apremilast 30 MG BID', 'through Week 52t', 'Placebo', 'Safety', '*Primary Endpoint -', '4-pt reduction', '(', '= Randomization', 'from BL in DLQI', 'BID = twice daily; BL = baseline; DLQI = Dermatology Life Quality Index.', '3.2.', 'Study Duration for Subjects', 'The study is designed as a 1-year (52-week) study, with a 4-week Post-treatment Observational', 'Follow-up Phase.', 'Visits will be scheduled at screening (no more than 5 weeks prior to randomization), Week', '0', '(baseline/randomization), Weeks 2, 4, 16, 20, 32, 44, and 52. Subjects who discontinue before', 'Confidential and Proprietary', '24', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
24,page_25,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Week 52 will be asked to attend an Early Termination visit. A post-treatment observational', 'follow-up will be conducted by phone at Week 56 for subjects who complete the 52-week study', 'treatment, or 4 weeks after study treatment discontinuation.', '3.3.', 'End of Trial', 'The End of Trial is defined as either the date of the last visit of the last subject to complete the', 'post-treatment follow-up, or the date of receipt of the last data point from the last subject that is', 'required for primary, secondary, and/or exploratory analysis, as pre-specified in the protocol,', 'whichever is the later date.', 'Confidential and Proprietary', '25', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
25,page_26,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '4.', 'STUDY POPULATION', '4.1.', 'Number of Subjects', 'Approximately 255 subjects will be enrolled in the study across approximately 6 to 10 countries', 'in Western Europe.', '4.2.', 'Inclusion Criteria', 'Subjects must satisfy the following criteria to be enrolled in the study:', '1.', 'Subject is > 18 years of age at the time of signing the informed consent form (ICF).', '2. Subject must understand and voluntarily sign an ICF prior to any study-related', 'assessments/procedures being conducted.', '3.', 'Subject is willing and able to adhere to the study visit schedule and other protocol', 'requirements.', '4.', 'Subject has diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline,', 'that cannot be controlled by topical therapy.', '5. Subject has a PASI score ranging from >3 to VI 10 at baseline.', '6. Subject has a DLQI score > 10 at baseline.', '7. Subject has presence of > 1 clinical manifestations of plaque psoriasis, defined as at least', 'one of the following:', 'a. Moderate to severe scalp psoriasis, defined as Scalp Physician Global Assessment', '(ScPGA) > 3', 'b. Nail psoriasis, defined as onycholysis and onychodystrophy in at least 2 fingernails', 'c. Moderate to severe genital plaque psoriasis, defined as modified static Physicians', 'Global Assessment of Genitalia (sPGA-G) > 3', 'd. Moderate to severe palmoplantar psoriasis, defined as Palmoplantar Psoriasis', 'Physicians Global Assessment (PPPGA) > 3', 'e.', 'Moderate to severe plaque psoriasis in visible locations (dorsal hand, face, neck, and', 'hairline) with static Physicians Global Assessment (sPGA) > 3', '8. Subject must be in general good health (except for psoriasis) as judged by the', 'Investigator, based on medical history, physical examination, and clinical laboratories.', '(NOTE: The definition of good health means a subject does not have uncontrolled', 'significant co-morbid conditions.)', '9. Subject must have failed to respond to, or be contraindicated to, or intolerant to other', 'systemic therapy including, but not limited to, cyclosporine, methotrexate, acitretin,', 'psoralen and ultraviolet-A-light (PUVA), fumaric acid esters or biologic therapies.', '10. Subjects (in Italy only) must be non-responder to, contraindicated to, or intolerant to', 'other systemic therapy (including cyclosporine, methotrexate, or PUVA) AND also be', 'contraindicated to, or intolerant to biologics.', 'Confidential and Proprietary', '26', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
26,page_27,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '11. Females of childbearing potential (FCBP)+ must have a negative pregnancy test at', 'Screening and Baseline. While on investigational product and for at least 28 days after', 'taking the last dose of investigational product, FCBP who engage in activity in which', 'conception is possible must use one of the approved contraceptive options described', 'below:', 'Option 1: Any one of the following highly effective methods: hormonal contraception', '(oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal', ""ligation; or partner's vasectomy;"", 'OR', 'Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of', 'natural [animal] membrane [for example, polyurethane]) PLUS one additional barrier', 'method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c)', 'contraceptive sponge with spermicide.', 'NOTE: Option 2 may not be acceptable as a highly effective contraception option in all', 'countries per local guidelines/regulations.', '4.3.', 'Exclusion Criteria', 'The presence of any of the following will exclude a subject from enrollment:', '1. Subject has any condition, including other inflammatory diseases or dermatologic', 'conditions, which confounds the ability to interpret data from the study, including other', 'types of psoriasis (ie, erythrodermic, or guttate), other than plaque psoriasis or inverse', 'psoriasis.', '2. Subject has history of drug-induced psoriasis.', '3. Subject has arthritis that requires disease-modifying antirheumatic drug (DMARD)', 'treatment.', '4. Subject unable to avoid use of tanning booths for at least 4 weeks prior to baseline and', 'during study.', '5. Subject is currently enrolled in any other clinical trial involving an investigational', 'product.', '6. Other than psoriasis, subject has history of clinically significant or uncontrolled disease', '(as determined by the Investigator), including the presence of laboratory abnormalities,', 'cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic,', 'immunologic disease, or other major disease, which places the subject at unacceptable', 'risk if he/she were to participate in the study.', 't A female of childbearing potential is defined as a sexually mature female who 1) has not undergone a', 'hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries)', 'or 2) has not been postmenopausal for at least 24 consecutive months (that is, has had menses at any time during', 'the preceding 24 consecutive months).', ""§ The female subject's chosen form of contraception must be effective by the time the female subject is randomized"", 'into the study (for example, hormonal contraception should be initiated at least 28 days before randomization).', 'Confidential and Proprietary', '27', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
27,page_28,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', ""7. Prior history of suicide attempt at any time in the subject's lifetime prior to signing the"", 'informed consent, or major psychiatric illness requiring hospitalization within the last 3', 'years prior to signing the informed consent.', '8. Subjects with severe renal impairment, defined by eGFR (estimated glomerular filtration', 'rate) or CLcr (creatinine clearance) less than 30 mL/min, are also categorized as having', 'Stage 4 Chronic Kidney Disease (CKD), and are excluded from the study.', '9. Malignancy or history of malignancy or myeloproliferative or lymphoproliferative', 'disease within the past 3 years, except for treated (ie, cured) basal cell or squamous cell', 'in situ skin carcinomas.', '10. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant', 'viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections', 'must have been completed and the infection cured, at least 4 weeks prior to Screening', 'and no new or recurrent infections prior to the Baseline Visit.', '11. Subject has received a live vaccine within 3 months of baseline or plans to do so during', 'study.', '12. Subject is a pregnant or breastfeeding (lactating) woman.', '13. Subject has used topical therapy within 2 weeks of randomization (including, but not', 'limited to, topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus,', 'pimecrolimus, anthralin/dithranol, or moisturizers which contain urea or salicylic acid).', 'Use of phototherapy within 4 weeks prior to randomization. Use of conventional', 'systemic therapy or systemic corticosteroids within 4 weeks prior to randomization,', 'except for conditions other than psoriasis or psoriatic arthritis. Use of biologic therapy', 'within 5 pharmacokinetic half-lives.', '14. Prior treatment with apremilast, or participation in a clinical study, involving apremilast.', '15. Subject has any condition that confounds the ability to interpret data from the study.', '16. Subject has history of allergy or hypersensitivity to any components of the IP (including', 'placebo).', '17. Subject has rare hereditary problem of galactose intolerance, lapp lactase deficiency or', 'glucose-galactose malabsorption.', 'Confidential and Proprietary', '28', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
28,page_29,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '5.', 'TABLE OF EVENTS', 'Table 3:', 'Table of Events', 'Post-Treatment', 'Screening', 'Placebo-Controlled Phase', 'Apremilast Extension Phaseb', 'Observational Follow-upd', 'Baseline', 'Visit Number', '1', '2', '3', '4', '5', '6', '7', '8', '9/ET°', '-35 to 0', '0', '2', '4', '16', '20', '32', '44', '52', '56 weeks (or 4 weeks after', 'Week', 'days', '(Day 1)', '( 3 days)', '( 3 days)', '( 3 days)', '(= 4 days)', '( 4 days)', '( 4 days)', '(= 4 days)', 'study discontinuation)', 'Informed consente', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Inclusion/Exclusion', 'X', 'X', '-', '-', '-', '-', '-', '-', '-', '-', 'criteria', 'Demographics', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Medical history', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Prior / concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'medications or therapies', 'Clinical and Laboratory Assessments', 'Adverse events', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Pregnancy test and', '-', '-', 'X', 'X', '-', '-', '-', '-', '-', 'X', 'contraception education', 'Vital signs', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'Height', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Weight', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'Waist Circumference', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'Body Mass Index', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Physical Examination', 'X', '-', '-', '-', '-', '-', '-', '-', '-', '-', 'Clinical laboratory', '-', '-', 'X', 'X', '-', '-', 'X', '-', 'X', 'X', 'evaluations-h,', 'Confidential and Proprietary', '29', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
29,page_30,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 3:', 'Table of Events (Continued)', 'Post-Treatment', 'Screening', 'Placebo-Controlled Phase', 'Apremilast Extension Phase', 'Observational Follow-upd', 'Baseline', 'Visit Number', '1', '2', '3', '4', '5', '6', '7', '8', '9/ETC', '56 (or 4 weeks after study', '-35 to 0', '0', '2', '4', '16', '20', '32', '44', '52', 'discontinuation)', 'Week', 'days', '(Day 1)', '(3 days)', '( 3 days)', '(=3 days)', '( 4 days)', '( 4 days)', '( 4 days)', '( 4 days)', 'Health-related Quality of Life and Efficacy Assessments', 'DLQI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'sPGA of Visible', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Location', 'ScPGAk', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Nail Assessment', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'NAPSI', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Modified sPGA-Gk', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'PPPGAK', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'Itch NRS', '-', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'Skin Discomfort/Pain', '-', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'VAS', 'PASI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'BSA', '-', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'EQ-5D', '-', 'X', '-', '-', 'X', '-', '-', '-', 'X', '-', 'PNQ', '-', 'X', '-', '-', '-', '-', '-', '-', '-', '-', 'PBQ', '-', '-', '-', 'X', 'X', '-', 'X', '-', 'X', '-', 'WPAI: PSO', '-', 'X', '-', '-', 'X', '-', '-', '-', 'X', '-', 'Photography""', '-', 'X', '-', '-', 'X', '-', 'X', '-', 'X', '-', 'Confidential and Proprietary', '30', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
30,page_31,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 3:', 'Table of Events (Continued)', 'Post-Treatment', 'Screening', 'Placebo-Controlled Phase', 'Apremilast Extension Phaseb', 'Observational Follow-upd', 'Baseline', 'Visit Number', '1', '2', '3', '4', '5', '6', '7', '8', '9/ETC', '56 (or 4 weeks after study', '-35 to 0', '0', '2', '4', '16', '20', '32', '44', '52', 'discontinuation)', 'Week', 'days', '(Day 1)', '(+3 days)', '( 3 days)', '( 3 days)', '( 4 days)', '( 4 days)', '( 4 days)', '( 4 days)', '-', '-', '-', '-', 'Dispense IP', 'X', 'X', 'X', 'X', 'X', 'X', 'Return and Count IP', '-', '-', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'Tablets', 'Abbreviations: BMI = body mass index; BSA = body surface area;', 'DLQI = Dermatology Life Quality Index; EQ-5D = European Quality of Life 5-', 'Dimension; FCBP = females of childbearing potential; IP = investigational product; NAPSI = Nail Psoriasis Severity Index; PASI = Psoriasis Area Severity Index; PBQ = Patient', 'Benefit Questionnaire; PNQ = Patient Needs Questionnaire; PPPGA = Palmoplantar Psoriasis Physicians Global Assessment; NRS = Numeric Rating Scale; ScPGA = Scalp', 'Physician Global Assessment; sPGA = static Physicians Global Assessment; sPGA-G = static Physicians Global Assessment of Genitalia; VAS = Visual Analog Scale;', 'WPAI:PSO = Work Productivity and Activity Impairment Questionnaire: Psoriasis.', 'a Visits in the Placebo-controlled Phase to be performed 3 days.', 'b Visits in the Apremilast Extension Phase to be performed 4 days.', 'c Visit 9 will serve as the Early Termination Visit for any subject who prematurely discontinues from the study, prior to Week 52. All subjects who complete the study or', 'discontinue the study early will be asked to enter the Four-week Post-treatment Observational Follow-up Phase.', 'd', 'Post-treatment observational follow-up will be conducted by telephone.', 'e Written informed consent will be obtained by the Principal Investigator or designee prior to initiation of any study procedures, including washouts from prior medications.', 'f Adverse event review should include new or worsening psychiatric symptoms, suicidal ideation, suicidal attempt, severe diarrhea, nausea and vomiting, and unexplained and', 'clinically significant weight loss. See Section 6.5.', 'g Females of childbearing potential (FCBPs) only. Serum pregnancy tests are performed at Screening, and Early Termination Visit/Last Treatment Visit. Urine pregnancy test kit', 'will also be provided to the site and performed at baseline prior to randomization. The Investigator will educate all FCBP about the different options of contraceptive methods', 'and their correct use at Screening and Baseline visits. The subject will be reeducated every time their contraceptive measures/methods or their ability to become pregnant', 'changes. A pregnancy test(s) should be administered if the FCBP subject misses a menstrual period.', 'h', 'Laboratory assessments will include routine/standard chemistry and hematology panel of tests. A lipid panel will be included in the standard chemistry panel. If screening', 'laboratory assessments are within 7 days of Baseline (Week 0), laboratory assessment does not need to be repeated at Baseline (Week 0). For females of childbearing potential', 'urine pregnancy test will be performed at Baseline (Week 0) to confirm subject eligibility (negative results required for IP administration).', 'j Subject assessments must be completed in the following order: DLQI, Itch NRS, Skin Discomfort/Pain VAS, EQ-5D, PNQ/PBQ, and WPAI: PSO, as scheduled in the Table of', 'Events.', 'k All manifestations should be assessed in all subjects at all visits, so that improvement, worsening, or new onset of any of these manifestations can be assessed.', '1', 'Nail assessments will evaluate presence of nail psoriasis, defined as onycholysis and onychodystrophy.', 'm Photographs will be obtained from subjects who provide separate consent to be photographed and at select sites only.', 'Confidential and Proprietary', '31', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
31,page_32,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.', 'PROCEDURES', 'The following procedures will be conducted as outlined in the Table of Events, Table 3.', '6.1.', 'Screening Period', 'Screening evaluations will be performed for all subjects to determine study eligibility. These', 'evaluations must be completed within 5 weeks of randomization. Subjects who do not meet', 'eligibility criteria for the study may be re-screened once, after a minimum of 35 days from the', 'date of their first screening.', 'Waivers to the protocol will not be granted during the conduct of this trial, under any', 'circumstances.', 'Safety laboratory analyses and all assessments will be performed (locally/centrally). Screening', 'laboratory values must demonstrate subject eligibility, but may be repeated once within the', 'screening window, if necessary.', 'The following will be performed at screening as specified in the Table of Events, after informed', 'consent has been obtained:', 'Demographics (year of birth, sex, and race, if allowed by local regulations, will be', 'collected).', 'Complete medical history', 'Prior and concomitant medications', 'Physical examination, height, weight, waist circumference, body mass index (see', 'Appendix O)', 'Vital signs (including blood pressure and heart rate)', 'Hematology panel including complete blood count (CBC) with differential, including red', 'blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH),', 'mean corpuscular hemoglobin concentration (MCHC), RBC Morphology, mean', 'corpuscular volume (MCV), white blood cell (WBC) count (with differential), and', 'platelet count.', 'Chemistry panel including sodium, potassium, calcium, chloride, blood urea nitrogen', '(BUN), creatinine, creatinine clearance, glucose, albumin, total protein, alkaline', 'phosphatase, bilirubin (total and direct), aspartate aminotransferase/serum glutamic', 'oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic pyruvic', 'transaminase (ALT/SGPT), gamma-glutamyl transferase (GGT), lactate dehydrogenase', '(LDH). A lipid panel will be included in the standard chemistry panel.', 'Pregnancy test is required for all female subjects of childbearing potential. Serum beta', 'human chorionic gonadotropin (B-hCG) pregnancy test will be performed at screening.', 'Urine (or serum) pregnancy test will be performed to assess subject eligibility within 72', 'Confidential and Proprietary', '32', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
32,page_33,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'hours prior to the first administration of IP, if the initial serum pregnancy test did not', 'already occur with 72 hours of dosing (negative results required for IP administration).', 'Contraception education will be performed by the Investigator at screening for all FCBP', 'about the options for and correct use of contraceptive methods at the Screening and', ""Baseline Visits and at any time when a FCBP's contraceptive measures or ability to"", 'become pregnant changes.', '-', 'A pregnancy test should be performed if the FCBP subject has missed a menstrual', 'period or the contraception method has changed', '- Counseling about pregnancy precautions and the potential risks of fetal exposure', 'must be conducted.', 'Adverse event assessment begins when the subject signs the informed consent form', 'Health-related quality of life and efficacy assessments to determine study eligibility,', 'including DLQI, sPGA of visible locations, ScPGA, NAPSI, modified sPGA-G, PPPGA,', 'and PASI', '6.2.', 'Treatment Period', 'The subject will begin treatment upon confirmation of eligibility. The subject must start', 'treatment within 35 days (5 weeks) of signing the ICF. An administrative window of 3 day is', 'permitted for Visits 3 and 4 and 4 days is permitted for Visits 5 through 9.', 'The following procedures will be conducted as outlined in the Table of Events, Table 3. The', 'evaluations should be performed prior to dosing on the visit day, unless otherwise specified.', 'Inclusion/Exclusion criteria (Baseline/Visit 2)', 'Concomitant medications and therapies evaluation', 'Vital signs', 'Weight, waist circumference', 'Adverse event evaluation (continuously and through 28 days after last dose of', 'apremilast)', 'Clinical laboratory evaluations [If screening laboratory assessments are within 7 days', 'of Baseline (Week 0), laboratory assessment does not need to be repeated at Baseline', '(Week 0)]', 'Efficacy assessment (see Section 6.4) [In addition to assessments specified in Table 3,', 'investigator will follow country guidelines to monitor therapy outcomes according to', 'clinical routine care and may assess efficacy or safety at any unscheduled visit and', 'document in source documents.]', 'Dispense IP', 'Return and count IP tablets', 'Urine (or serum) pregnancy test (prior to dosing on Day 1)', 'Confidential and Proprietary', '33', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
33,page_34,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.2.1.', 'End of Treatment', 'An end of treatment (EOT) evaluation will be performed for subjects who are withdrawn from', 'treatment for any reason as soon as possible after the decision to permanently discontinue', 'treatment has been made. The end of treatment (Visit 9) assessments will also be performed for', 'subjects who complete the study.', 'The following evaluations will be performed as specified in the Table of Events:', 'Weight, waist circumference', 'Vital signs', 'Concomitant medications and therapies evaluation', 'Adverse event evaluation (through 28 days past last dose of apremilast)', 'Clinical laboratory evaluations', 'Serum pregnancy test for females of childbearing potential (B-subunit of human chorionic', 'gonadotropin [Serum ß-hCG])', 'Counseling about pregnancy precautions and the potential risks of fetal exposure must be', 'conducted', 'Return and count IP tablets', 'Efficacy assessment', '6.3.', 'Follow-up Period', '6.3.1.', 'Post-Treatment Observational Follow-up', 'All subjects will be followed for 28 days after the last dose of apremilast for AE reporting , as', 'well as all SAEs made known to the Investigator at any time following the protocol-required', 'reporting period or after end of study, as described in Section 10.1. A 4-week post-treatment', 'observational follow-up will be conducted by telephone at Week 56 for subjects who complete', 'the 52-week study treatment or 4 weeks after study treatment discontinuation.', '6.4.', 'Efficacy Assessments', 'The following assessments will be conducted as outlined in the Table of Events, Table 3.', '6.4.1.', 'The Dermatology Life Quality Index (DLQI)', 'The DLQI (Finlay, 1994) will be assessed by the subject upon arrival at the site', 'before any other procedures or assessments are performed. The DLQI was developed', 'as a simple, compact, and practical questionnaire for use in a dermatology clinical', 'setting to assess limitations related to the impact of skin disease (Finlay, 1994). The', ""instrument contains 10 items pertaining to the subject's skin. With the exception of"", 'Item Number 7, the subject responds on a four-point scale, ranging from ""Very', 'Much"" to ""Not at All."" Item Number 7 is a multi-part item, the first part of which', ""ascertains whether the subject's skin prevented them from working or studying (Yes"", 'or No), and if ""No,"" then the subject is asked how much of a problem the skin has', 'Confidential and Proprietary', '34', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
34,page_35,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'been at work or study over the past week, with response alternatives being ""A lot,""', '""A little,"" or ""Not at all.""', 'The DLQI total score has a possible range from 0 to 30, with 30 corresponding to the', 'worst quality of life, and 0 corresponding to the best score. The developers suggest', 'that the DLQI can be grouped into six subscales: symptoms and feelings, daily', 'activities, leisure, work/school, personal relationships, and treatment. Scores for four', 'of the subscales (symptoms and feelings, daily activities, leisure, and personal', 'relationships) range from 0 to 6; scores for two of the subscales (work/school and', 'treatment) range from 0 to 3. Higher scores correspond to poorer quality of life. See', 'Appendix B.', '6.4.2.', 'Static Physicians Global Assessment (sPGA) of Visible Locations', 'The sPGA is the assessment by the Investigator of the overall disease severity at the', 'time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe),', 'incorporating an assessment of the severity of the three primary signs of the disease:', 'erythema, scaling and plaque elevation. In this study, sPGA is used to evaluate', 'psoriasis only in visible locations, defined as dorsal hand, face, neck and hairline.', 'When making the assessment of overall severity, the investigator should factor in', 'areas that have already been cleared (ie, have scores of 0) and not just evaluate', 'remaining lesions for severity, ie, the severity of each sign is averaged across all areas', 'of involvement, including cleared lesions. In the event of different severities across', 'disease signs, the sign that is the predominant feature of the disease should be used to', 'help determine the sPGA score. See Appendix C for grading criteria.', '6.4.3.', 'Scalp Physician Global Assessment (ScPGA)', 'The ScPGA will assess scalp involvement. See Appendix D for grading criteria. The', '5-point ScPGA scale ranges from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to', '4 (severe).', '6.4.4.', 'Nail Assessments/Nail Psoriasis Severity Index (NAPSI)', 'The number of fingers with psoriasis nail involvement, defined as onycholysis and', 'onychodystrophy, will be counted.', 'The NAPSI will assess one target thumb nail or fingernail representing the worst nail', 'psoriasis involvement at Baseline. See Appendix E for grading criteria.', '6.4.5.', 'Modified static Physicians Global Assessment of Genitalia (Modified sPGA-G)', 'The modified sPGA-G is the assessment by the Investigator of the overall disease', 'severity at the time of evaluation of the genital regions. The assessment area includes', 'the vulvar region in women, from the clitoral prepuce to the perineum, and the penis,', 'scrotum, and perineum in men. It does not include the pubis, inguinal folds, peri-anal', 'region, or gluteal cleft; however, in this study, the assessment will be modified to also', 'include the peri-anal region and gluteal cleft. As with the sPGA, it is a 5-point scale,', 'ranging from 0 (clear) to 4 (severe). Note that not all three individual features will', 'always be present on evaluation. Thus, while the total represents a combination of the', 'Confidential and Proprietary', '35', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
35,page_36,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'three features, it should be primarily determined by the degree of erythema, as that is', 'the dominant feature in the majority of cases of genital psoriasis (Merola, 2017).', 'Appendix F.', '6.4.6.', 'Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)', 'The PPPGA is the assessment by the Investigator of the overall disease severity at the', 'time of evaluation of palms and soles (Leonardi, 2007). The scale ranges from', 'ranging from 0 (clear) to 4 (severe). See Appendix G.', '6.4.7.', 'Itch Numeric Rating Scale (NRS)', 'The Itch NRS is a single-item patient-reported outcome that asks subjects to assess', 'the worst severity of itch over the past 24 hours. Subjects indicate itch severity by', 'circling the number that best describes the worst level of itching due to psoriasis in', 'the past 24 hours on an 11-point scale anchored at 0, representing ""no itching\' and 10,', 'representing ""worst itch imaginable\' (Naegeli, 2015). See Appendix H.', '6.4.8.', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', 'The subject will be asked to place a vertical stroke on a 100 mm VAS on which the', 'left-hand boundary represents no skin discomfort/pain, and the right-hand boundary', 'represents skin discomfort/pain as severe as can be imagined. The distance from the', 'mark to the left-hand boundary will be recorded. See Appendix I.', '6.4.9.', 'Body Surface Area (BSA)', 'Body surface area is a measurement of involved skin. The overall BSA affected by', ""psoriasis is estimated based on the palm area of the subject's hand (entire palmar"", 'surface or ""handprint""), which equates to approximately 1% of total BSA.', '6.4.10.', 'Psoriasis Area Severity Index (PASI)', 'The PASI will be determined for all subjects throughout the study. The PASI', 'calculation is described in Appendix J.', 'The PASI is a measure of psoriatic disease severity taking into account qualitative', 'lesion characteristics (erythema, thickness, and scaling) and degree of skin surface', 'area involvement on defined anatomical regions. The PASI is a validated instrument', 'that has become standard in clinical trials for psoriasis.', 'The PASI scores range from 0 to 72, with higher scores reflecting greater disease', 'severity (Fredriksson, 1978). Erythema, thickness, and scaling are scored on a scale', 'of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper', 'limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is', 'scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total', 'qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the', 'degree of involvement for each anatomic region and then multiplied by a constant.', 'These values for each anatomic region are summed to yield the PASI score.', 'Confidential and Proprietary', '36', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
36,page_37,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.4.11.', 'Patient Benefit Index (PBI)', 'The PBI is a validated patient-reported instrument to assess patient-relevant benefits', 'of psoriasis treatment (Feuerhahn, 2012). Prior to starting therapy, subjects are asked', 'to assess their treatment expectations by completing the Patient Needs Questionnaire', '(PNQ) (See Appendix K). After a period of treatment, subjects are then asked to', 'assess the benefits of treatment by completing the Patient Benefit Questionnaire', '(PBQ) (See Appendix L). The Patient Benefit Index represents the subject benefits', 'realized as a function of most important subject needs. The PBI score ranges from 0', '(no benefit) to 4 (maximum benefit).', '6.4.12.', 'The European Quality of Life 5-Dimension Questionnaire (EQ-5D)', ""EQ-5D (The EuroQol Group, 1990) measures the subject's general health state as a"", 'vertical VAS and 5 quality of life domains as multiple-choice questions: mobility,', 'self-care, main activity (work, study, housework, family/leisure activities),', 'pain/discomfort, and anxiety/depression, the combination of which generates 243', 'possible health states. See Appendix M.', '6.4.13.', 'The Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI: PSO)', 'The WPAI: PSO questionnaire is a validated, 6-item self-administered instrument', 'used to assess the impact of disease on work productivity in psoriasis due to general', 'health or a specified health problem (Reilly, 2012; Appendix N).', '6.4.15.', 'Photography', 'Photographs will be collected only at selected sites, in subjects who consent, and will', 'be considered as supportive evidence of efficacy. Descriptive summary of', 'photography will be addressed in the statistical analysis plan (SAP) and included in', 'the clinical study report.', 'Confidential and Proprietary', '37', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
37,page_38,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Photographs will be taken of all effected manifestations of plaque psoriasis at Weeks', '0, 16, 32, and 52. Appropriate protective mechanisms shall be implemented to ensure', 'that the photographs do not contain any subject-specific identifiers (such as tattoos,', 'scars, etc) when shared with the Sponsor.', 'The procedure for taking the photographs and processing and shipping photographs', 'will be described in a separate procedure manual distributed to investigational sites', 'performing photographic assessments.', 'Photographic assessments are an optional part of this study. Subjects enrolled at the', 'selected photography sites will be asked to sign a separate consent form specific to', 'photography at Visit 1 (Screening Visit), prior to being photographed.', '6.5.', 'Safety Assessments', 'In addition to safety monitoring conducted by Investigators and individual study personnel, AEs,', 'serious adverse events (SAEs), discontinuations and laboratory findings will be reviewed by the', 'study team. The review follows the Council for International Organizations for Medical', 'Sciences, Working Group VI (CIOMS VI) recommendations.', 'The study will be conducted in compliance with the ICH of Technical Requirements for', 'Registration of Pharmaceuticals for Human Use/GCP and applicable regulatory requirements.', 'The following assessments will be conducted as outlined in Table 3, Table of Events.', '6.5.1.', 'Serum and Urine Pregnancy Tests for Females of Childbearing Potential', 'A serum pregnancy test with a sensitivity of < 15 mIU/mL will be required for FCBP subjects at', 'Screening and the Week 52 Visit (or at the Early Termination Visit for subjects who prematurely', 'discontinue from the study). Urine pregnancy test will be performed on all FCBP subjects at the', 'Baseline Visit, prior to randomization. A urine pregnancy test kit will be provided by the central', 'laboratory. Pregnancy tests should be performed if the FCBP subject has missed a menstrual', 'period or the contraception method has changed.', '6.5.2.', 'Vital Signs, Weight and Waist Circumference', 'Vital signs, including pulse, and seated blood pressure, will be taken during the visits indicated', 'in Table 3, Table of Events. Weight and waist circumference will be measured and recorded at', 'the Screening Visit and then as indicated in Table 3, Table of Events; Body mass index (BMI)', 'will be calculated programmatically based on the Height measured and recorded at Screening. In', 'the event of unexplained and clinically significant weight loss, the patients should be evaluated', 'by the investigator and discontinuation of treatment should be considered (see Section 11).', '6.5.3.', 'Physical Examination', 'A physical examination includes evaluations of skin, nasal cavities, eyes, ears, lymph nodes, and', 'respiratory, cardiovascular, gastrointestinal, neurological, and musculoskeletal systems. A', 'physical examination is done at Screening as indicated in Table 3, Table of Events. Additional', 'physical examinations may be performed during the course of study as deemed necessary per', ""investigator's judgment and recorded in source documents."", 'Confidential and Proprietary', '38', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
38,page_39,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.5.4.', 'Psychiatric Evaluation', 'Treatment with apremilast is associated with an increase in adverse reactions of depression.', 'Before using apremilast in subjects with a history of depression and/or suicidal thoughts or', 'behavior, the Investigator should carefully weigh the risks and benefits of treatment with', 'apremilast in such patients. Subjects should be advised of the need to be alert for the emergence', 'or worsening of depression, suicidal thoughts or other mood changes, and if such changes occur', 'to contact the Investigator.', 'If a patient suffers from new or worsening psychiatric symptoms, or suicidal ideation is', 'identified, it is recommended to discontinue the subject participation to the study. Subjects who', 'are identified by the Investigator as having attempted suicide must be immediately withdrawn', 'from the study (see Section 11).', '6.5.5.', 'Severe Diarrhea, Nausea and Vomiting', 'There have been post-marketing reports of severe diarrhea, nausea, and vomiting associated with', 'the use of apremilast. Most events occurred within the first few weeks of treatment. In some', 'cases, patients were hospitalized. Patients 65 years of age or older and patients taking', 'medications that can lead to volume depletion or hypotension may be at a higher risk of', 'complications. Subjects should be monitored for severe diarrhea, nausea and vomiting. If', 'patients develop severe diarrhoea, nausea, or vomiting, discontinuation of treatment may be', 'necessary (see Section 11).', '6.5.6.', 'Clinical Laboratory Evaluations', 'Clinical laboratory evaluations will be performed as indicated in Table 3, Table of Events. These', 'include complete blood count (red blood cell [RBC] count, hemoglobin, hematocrit, white blood', 'cell [WBC] count and differential, absolute WBC counts, platelet count) and serum chemistries', 'including sodium, potassium, calcium, chloride, blood urea nitrogen (BUN), creatinine,', 'creatinine clearance, glucose, albumin, total protein, alkaline phosphatase, bilirubin (total and', 'direct), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT),', 'alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT), gamma-glutamyl', 'transferase (GGT), lactate dehydrogenase (LDH). A lipid panel will be included in the standard', 'chemistry panel.', '6.5.7.', 'Tuberculosis', 'After an extensive clinical development program, there is no current evidence that apremilast has', 'the potential to activate latent TB. Therefore, no TB testing will be done in this protocol.', ""Investigators can test for TB if clinically indicated, using the site's local or country-specific"", 'guidelines. If the subject has active or latent TB, he/she should be treated according to local', 'guidelines. Subjects who require TB treatment at any time during the study must be', 'discontinued.', 'Confidential and Proprietary', '39', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
39,page_40,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.5.8.', 'Adverse Events', 'All subjects will be monitored for adverse events (AEs) during the study. Assessments may', ""include monitoring of any or all of the following parameters: the subject's clinical symptoms,"", 'laboratory, radiological, or surgical findings; physical examination findings; psychiatric', 'evaluation; or other appropriate tests and procedures.', 'All AEs will be recorded by the Investigator from the time the subject signs informed consent to', '28 days after the last dose of IP. Adverse events and serious adverse events (SAEs) will be', 'recorded on the AE page of the electronic case report form (eCRF), the paper SAE reporting', ""form (SAEs) and in the subject's source documents. All SAEs must be reported to Amgen"", ""Global Patient Safety within 24 hours of the Investigator's knowledge of the event by recording"", 'on the CRF and using the paper Serious Adverse Event Report Form by facsimile/email of the', 'paper SAER Form directly to Amgen Global Patient Safety.', 'Details of AE reporting can be found in Section 10.1 of the protocol.', 'Confidential and Proprietary', '40', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
40,page_41,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '7.', 'DESCRIPTION OF STUDY TREATMENTS', '7.1.', 'Description of Investigational Product(s)', 'The chemical name of apremilast (CC-10004) is acetamide, N-[2-[(1S)-1-(3-ethoxy-e', 'methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl].', 'Apremilast will be provided by Amgen as 10, 20, or 30 mg tablets in blister cards for dose', 'titration purposes. Apremilast will also be provided as 30 mg tablets in high-density polyethylene', '(HDPE) bottles (approximately 80 tablets) with child-resistant caps.', 'Identically-appearing placebo tablets will also be provided by Amgen in blister cards.', '7.2.', 'Treatment Administration and Schedule', 'Subjects will be dispensed blister cards with 10, 20, and 30 mg apremilast tablets, or identically', 'appearing placebo, for the dose titration, at the baseline visit (Week 0) and Week 16.', 'Starting at Week 16, all subjects will be switched to, or will continue with, apremilast. Subjects', 'originally randomized to placebo at Week 0 will be switched to apremilast at Week 16. At all', 'visits (Week 0 to Week 16), titration / treatment will be dispensed in blister cards with apremilast', 'or placebo tablets and will be identically appearing. Beginning with the Week 20 visit, all', 'subjects will receive open label HDPE bottles of IP tablets. All subjects will maintain this', 'dosing through Week 52.', 'Apremilast or placebo tablets will be taken orally twice daily, approximately 12 hours apart,', 'through the last treatment visit.', 'The titration blister card configurations are pictured in Appendix R. The treatment schema for', 'dose titration at Baseline is shown in Appendix P, and at Week 16 is shown in Appendix Q.', 'Dose modifications are not permissible in this study.', '7.3.', 'Method of Treatment Assignment', 'After the informed consent is signed, subjects will be assigned a subject identification number', 'using a centralized interactive response technology (IRT). At the Baseline Visit, a centralized', 'schema will be applied to assign subjects who meet the eligibility criteria in a 2:1 ratio to receive', 'either apremilast 30 mg tablets orally BID or identically-appearing placebo tablets using the IRT.', 'Subjects will be block-randomized to each of the manifestations of plaque psoriasis specified in', 'the protocol. If subjects present with multiple manifestations, they will be allocated to the', 'manifestation which is most severe, as determined by the subject at the screening and baseline', 'visits. However, all manifestations will be assessed for efficacy at each study visit.', 'Designated research personnel at the investigational sites will be assigned password protected,', 'coded identification numbers, which gives them authorization to enter the IRT to randomize', 'subjects. The system will present a menu of questions by which the research center personnel', 'will identify the subject and confirm subject eligibility. When all questions have been answered', 'and the subject deemed eligible, the IRT will assign a randomization identification number.', 'Confirmation of the randomization will be sent to the investigational site, Amgen, and/or its', 'representative. The confirmation reports should be maintained as source documents. During the', 'Confidential and Proprietary', '41', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
41,page_42,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'study visits, the pharmacy or authorized study personnel at the investigational site will dispense', 'coded IP kits in accordance with the randomization number assigned by the IRT.', '7.4.', 'Packaging and Labeling', 'The label(s) for IP will include Sponsor name, address and telephone number, the protocol', 'number, IP name, dosage form and strength (where applicable), amount of IP per container, lot', 'number, expiry date (where applicable), medication identification/kit number, dosing', 'instructions, storage conditions, and required caution statements and/or regulatory statements as', 'applicable. Additional information may be included on the label as applicable per local', 'regulations.', 'All IP tablets, including apremilast and identically-appearing placebo, will be supplied by', 'Amgen. Investigational product for dose titration at Baseline and to Week 20 will be supplied in', 'blister cards. Investigational product tablets at Week 20 and through Week 52 will be supplied in', 'open label HDPE bottles with child-resistant caps.', '7.5.', 'Investigational Product Accountability and Disposal', 'The Investigator, or designee, is responsible for taking an inventory of each shipment of oral IP', 'received, and comparing it with the accompanying IP shipping order/packing list.', 'The Investigator, or designee, will verify the accuracy of the information on the form, sign and', 'date it, retain a copy in the study file, and record the information in the IRT..', 'Investigational product will be stored per the storage conditions identified on the IP label. At the', 'study site, all IP will be stored in a locked, safe area to prevent unauthorized access.', 'Amgen (or designee) will review with the Investigator and relevant site personnel the process for', 'IP return, disposal, and/or destruction including responsibilities for the site versus Amgen (or', 'designee).', '7.6.', 'Investigational Product Compliance', 'Study personnel will review the instructions printed on the package with the study subjects prior', 'to dispensing the IP in tablet form (both blister cards and bottles). Investigational product will be', 'dispensed as noted in the Table of Events, Table 3. The subjects will be instructed to return the', 'IP containers, including any unused medication, to the study site at each visit for tablet counts', 'and reconciliation. At each study visit, subjects will be asked whether they have taken their IP as', 'instructed. Any problems with IP compliance will be reviewed with the subject. If a subject', 'misses 4 or more consecutive days of dosing, Amgen should be contacted to decide whether', 'dosing should resume or whether the subject should be terminated from the Treatment Phase of', 'the study, and enter into the Posttreatment Observational Follow-up Phase.', 'Gross compliance problems (eg, missing 4 or more consecutive days of dosing or taking less', 'than 75% of the doses between study visits) should be discussed with Amgen. Compliance is', 'defined as taking between 75% and 120% of dispensed IP.', 'Confidential and Proprietary', '42', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
42,page_43,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '7.7.', 'Overdose', 'Overdose, as defined for this protocol, applies to protocol-required dosing of the investigational', 'product(s) (IPs) only. Therefore, for a drug to be subject to the overdose definition it must be', 'both required and an investigational drug. In this study the only required and investigational', 'drug is apremilast and the control arm drug (ie, placebo), hence overdose definition will apply to', 'only apremilast (or matching placebo). Other required or optional non-study drugs intended for', 'prophylaxis of certain side effects, etc, are excluded from this definition.', 'Overdose for this protocol, on a per dose basis, is defined as ingestion of 4 or more 30 mg', 'apremilast (or matching placebo) tablets in any 24-hour period, whether by accident or', 'intentionally. On a schedule or frequency basis, an overdose is defined as dosing more than 4', 'times during any 24-hour period.', 'Adverse Events associated with an overdose must be collected on the Adverse Events page of the', 'eCRF (see Section 10.1) for all overdosed subjects, but the overdose itself is not considered an', 'AE.', 'Confidential and Proprietary', '43', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
43,page_44,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '8.', 'CONCOMITANT MEDICATIONS AND PROCEDURES', '8.1.', 'Permitted Concomitant Medications and Procedures', 'Subjects may take any medication that is not restricted by the protocol and would not be', 'expected to interfere with the conduct of the study or affect assessments. Chronic medication', 'should be dosed on a stable regimen.', 'All medications (prescription and non-prescription), treatments, and therapies taken by the', 'subject from signing the informed consent throughout their entire participation in the study,', 'including those initiated prior to signing the informed consent and continued through the start of', ""the study, must be recorded on the subject's source document and on the appropriate page of the"", 'eCRF. The dose, unit, frequency, route, indication, the date the medication was started, and the', 'date the medication was stopped (if not ongoing) must be recorded.', 'During the study, the initiation of new concomitant medications or a change of existing', 'concomitant medications may potentially indicate the presence of a new adverse event or the', 'worsening of an existing condition. If appropriate, such events should be recorded in the eCRF.', 'The following topical therapies will be permitted throughout the study:', 'Unmedicated skin moisturizers will be permitted for body lesions only.', '- Permitted skin moisturizers may not contain urea or salicylic acid.', '8.2.', 'Concomitant Medications Not Recommended', 'Co-administration of the strong cytochrome P450 3A4 (CYP3A4) enzyme inducer, rifampicin,', 'resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy', 'of apremilast. Therefore, the use of strong CYP3A4 enzyme inducers (eg, rifampicin,', ""phenobarbital, carbamazepine, phenytoin and St. John's Wort) with apremilast is not"", 'recommended during the study.', '8.3.', 'Prohibited Concomitant Medications and Procedures', 'The following psoriasis medications cannot be administered for the duration of the study.', 'Topical therapy', '- Topical therapy, unless otherwise specified in Section 8.1 (including, but not', 'limited to topical corticosteroids, retinoids or Vitamin D analog preparations,', 'tacrolimus, pimecrolimus, coal tar, anthralin/dithranol, or urea- and salicylic acid-', 'containing moisturizers)', 'Conventional systemic therapy', '- Conventional systemic therapy including but not limited to cyclosporine,', 'methotrexate, retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus,', 'sulfasalazine, azathioprine, fumaric acid esters, and corticosteroids', 'Biologic agents, including:', 'Confidential and Proprietary', '44', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
44,page_45,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '- Adalimumab, etanercept, infliximab, or certolizumab pegol, ustekinumab,', 'secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab', 'Phototherapy', '- Ultraviolet light B (UVB) or psoralens and long-wave ultraviolet radiation', '(PUVA)', 'Use of any investigational drug or device', 'Use of tanning booths, which may confound the ability to interpret data from the', 'study.', '8.4.', 'Required Concomitant Medications and Procedures', 'Not applicable.', 'Confidential and Proprietary', '45', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
45,page_46,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '9.', 'STATISTICAL CONSIDERATIONS', '9.1.', 'Overview', 'The objective of this study is to evaluate the health-related quality of life, efficacy, and safety of', 'apremilast compared to placebo, for 16 weeks, and evaluate the long-term effects of apremilast', 'on quality of life, efficacy, and safety for up to 52 weeks in subjects with manifestations of', 'plaque psoriasis and impaired quality of life.', '9.2.', 'Study Population Definitions', 'Four analysis populations will be defined for this study. These populations include the safety', 'population, the intent to treat (ITT) population, the per protocol (PP) population, and the', 'apremilast exposure population.', 'The Safety population will consist of all subjects who are randomized and receive at', 'least one dose of investigational product (IP). This set of subjects will be included in', 'the treatment group corresponding to the IP they actually receive. This will be the', 'population for all safety analyses on data from the Placebo-controlled Phase.', 'The ITT population will consist of all subjects who are randomized. This will be the', 'primary population for the primary endpoint and all other quality of life and efficacy', 'analyses. Baseline summaries will also be based on the ITT population.', 'The PP population will consist of all subjects who are in the ITT population,', 'complete the Placebo-controlled Phase, and have no major protocol violations. The', 'PP population will only be used to supplement the primary endpoint ITT analysis.', 'The apremilast (APR) exposure population will consist of only those subjects who', 'receive at least one dose of apremilast treatment. The APR exposure population will', 'only be used for the purposes of safety reporting including all safety data during', 'apremilast treatment.', '9.3.', 'Sample Size and Power Considerations', 'Using an exploratory analysis on a subset of subjects meeting the following criteria: 1) ScPGA >', '3 at baseline or 2) NAPSI > 1 at baseline or PPPGA > 3 at baseline and DLQI > 10 at baseline in', 'the PSOR-008 and PSOR-009 Phase 3 studies, it was estimated that the proportion of subjects', 'who achieved a > 4-point reduction from baseline in DLQI was 0.50 (97 responders out of 193', 'subjects) and 0.83 (337 responders out of 406 subjects) for placebo and apremilast 30 mg,', 'respectively.', 'Assuming a placebo DLQI Responder proportion of 0.50 at Week 16, a minimum total sample', 'size of 210 subjects (140 allocated to apremilast 30 mg and 70 allocated to placebo) is needed to', 'detect a 0.20 difference in the DLQI Responder proportions between apremilast and placebo with', 'at least 0.807 power using a two-sided test at the 0.05 level of significance. This sample size', 'calculation is based on an unpooled variance, and was determined using the commercial software', 'EaST, Version 6.3. Allowing for a 18% discontinuation rate prior to Week 16, the sample size', 'was revised from a total of 210 subjects to a final sample size of 255. If there are no', 'discontinuations prior to Week 16, then the power with a sample size of 255 subjects would', 'Confidential and Proprietary', '46', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
46,page_47,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'increase to 0.872. Hence when addressing missing data due to discontinuations with multiple', 'imputations, we would expect the power to be in between the bounds of 0.807 (based on 210', 'subjects) and 0.872 (based on 255 subjects), as the analysis that incorporates multiple imputation', 'under a missing at random assumption will always be more efficient compared to the observed', 'analysis when the missing data is actually missing completely at random.', '9.4.', 'Background and Demographic Characteristics', ""Subjects' age, height, weight, and baseline characteristics will be summarized using descriptive"", 'statistics, while sex, race, and other categorical variables will be provided using frequency', 'tabulations. The disease characteristics at baseline will also be summarized using appropriate', 'descriptive statistics. These descriptive statistics will be summarized by the randomized', 'treatment group using the ITT population.', '9.5.', 'Subject Disposition', 'The distribution of enrollment by site will be provided. Subject disposition (analysis population', 'allocation, entered, completed, discontinued, along with primary reason for discontinuation) will', 'be summarized using frequency and percent for the Placebo-controlled Phase (Weeks 0 to 16)', 'and the apremilast Extension Phase (Weeks 16 to 52). Protocol deviations will be summarized', 'using frequency tabulations.', '9.6.', 'Efficacy Analysis', 'Statistical comparisons will be made between apremilast and placebo at Week 16. The statistical', 'test on the primary endpoint will be at a 2-sided 0.05 significance level with treatment effect', 'estimates and the corresponding 95% confidence intervals (CIs) being reported. Any p-values', 'reported other than for the primary endpoint analysis will be considered as summary statistics.', 'Descriptive statistic summaries for the observed data will also be provided by visit and', 'randomized treatment group.', '9.6.1.', 'Primary Endpoint', 'The primary endpoint is the proportion of subjects achieving a > 4 point reduction from baseline', 'in DLQI at Week 16. It will be analyzed using the ITT population. However, a supplemental', 'analysis will be performed using the PP population.', 'The primary analysis for the primary endpoint at Week 16 will be the Cochran-Mantel-Haenszel', '(CMH) test adjusted for the stratification factor at randomization (ie, the 5 difficult to treat', 'manifestation types). This form of the CMH test will use the sample sizes in each of the strata as', 'weights when estimating the adjusted difference in the treatment proportions, constructing 95%', 'Wald confidence intervals for the difference, and conducting a statistical test of no difference', 'between the treatment proportions (ie, Ho: TAPR - TPBO = 0 as the null hypothesis).', 'All reasonable attempts will be made to prevent missing data from occurring in this study,', 'especially through Week 16. However, in the case of missing data at Week 16 a multiple', 'imputation (MI) method will be incorporated into the primary analysis. Imputations will be made', 'on the continuous-like scale of the total DLQI score, and then dichotomized according to the', 'primary endpoint definition prior to performing the CMH analysis. The aim of the multiple', 'Confidential and Proprietary', '47', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
47,page_48,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'imputation approach is to incorporate a representative random sample in place of the missing', 'data such that unbiased estimation and valid statistical inferences (ie, confidence intervals and', 'hypothesis testing) can be made.', 'Details with respect to the construction of the CMH test statistic, multiple imputation procedure', 'and the terminal analysis method for combining the multiple imputation results, as well as all', 'supportive sensitivity and subgroup analyses involving the stratums for the primary endpoint will', 'be specified in the SAP.', '9.6.2.', 'Secondary and Exploratory Efficacy Enppoints', 'For continuous endpoints at Week 16, an analysis of covariance (ANCOVA) model with', 'treatment and randomization strata as fixed effects and corresponding baseline value as a', 'continuous covariate will be employed. Missing data will be addressed using multiple', 'imputation. The adjusted means and standard errors will be reported for each of the treatment', 'group using the ANCOVA model, as well as the estimated treatment effect (ie, difference in the', 'adjusted treatment means, their standard errors, and 95% confidence intervals). In addition,', 'descriptive statistics will be provided based upon the observed data which will not address', 'missing data. Details regarding the methods of estimation to be performed at Weeks 32 and 52', 'will be provided in the statistical analysis plan (SAP).', 'For discrete endpoints, the CMH estimation method stratified by the randomization strata for', 'assessing the difference in proportion between the treatment groups will be conducted. The', 'weights in the CMH estimation method will be same as those used in the primary endpoint', 'analysis. The adjusted difference in the proportions between the treatment groups, their standard', 'errors, and corresponding 95% confidence intervals will be reported. Missing data will be', 'addressed through multiple imputation similar to that of the primary endpoint analysis. In', 'addition, descriptive statistics involving the sample size, the number of responders, and', 'proportion of responders will be summarized by treatment group. Details regarding the methods', 'of estimation to be performed at Weeks 32 and 52 will be provided in the SAP.', '9.6.3.', 'Photography', 'Photographs will be collected only at selected sites in subjects who consent and will be', 'considered as supportive evidence of efficacy. Descriptive summary of photography will be', 'addressed in the SAP and included in the clinical study report.', 'Photographs will be taken of all effected manifestations of plaque psoriasis at Weeks 0, 16, 32,', 'and 52.', 'Subjects must sign a separate consent form specific to Photography at Visit 1 (Screening Visit).', 'Confidential and Proprietary', '48', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
48,page_49,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '9.6.5.', 'Multiplicity Adjustment', 'There will be no multiplicity adjustment. Only the primary endpoint analysis will be used to', 'declare a statistical significance.', '9.7.', 'Safety Analysis', 'The safety analyses will be performed using the safety population as defined in Section 9.2,', 'defined as all subjects who are randomized and receive at least one dose of investigational', 'product. Safety will be assessed by clinical review of all relevant parameters including treatment-', 'emergent adverse events (TEAEs), laboratory tests, and vital signs; no inferential testing for', 'statistical significance will be performed. Data from safety assessments will be summarized', 'descriptively for the Placebo-controlled Phase (Weeks 0 to 16) and the Apremilast Exposure', 'Period when subjects receive apremilast treatment. For safety analyses in the Placebo-controlled', 'Phase, baseline will be relative to the first dose date following randomization at Week 0. For', 'safety analyses in Apremilast Exposure Period, baseline will be relative to the first apremilast', 'dose date at Week 0 for subjects initially randomized to apremilast or Week 16 for subjects', 'initially randomized to placebo and switched to apremilast in the Apremilast Extension Phase', '(Weeks 16-52).', 'Adverse events will be classified using the Medical Dictionary for Regulatory Activities', '(MedDRA) classification system. Adverse events will be tabulated by study phase (Double-blind', 'Placebo-controlled Phase or apremilast Exposure Phase). All treatment-emergent adverse events', '(AEs) will be summarized by system organ class, preferred term, severity, and relationship to IP.', 'Adverse events leading to death or to discontinuation from treatment and serious AEs will also', 'be summarized and listed separately.', 'Laboratory data will be summarized using shift tables showing the number of subjects with low,', 'normal, and high values based on the normal ranges, pretreatment versus post-treatment.', 'Vital sign measurements, including weight, will be summarized by visit descriptively (count,', 'mean, median, standard deviation, and range). In addition, shift tables showing the number of', 'subjects with values below, within and above the normal reference ranges pretreatment versus', 'post-treatment will be provided.', 'The changes and percent changes in body weight will be summarized by visit. In addition, the', 'changes by baseline body mass index (BMI; (< 18.5, 18.5 to < 25, 25 to < 30, 30 to < 35, 35 to', '< 40, > 40 kg/m²) will be explored.', '9.8.', 'Interim Analysis', 'No interim analysis is planned for this study.', '9.9.', 'Other Topics', '9.9.1.', 'Investigational Product Compliance (Tablets)', 'Investigational product record information will be summarized. Overall compliance will be', 'estimated by the proportion of subjects who take between 75% and 120% of the intended', 'quantity of IP.', 'Confidential and Proprietary', '49', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
49,page_50,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '9.9.2.', 'Concomitant Therapy', 'All concomitant treatments documented during the study period will be summarized in frequency', 'tabulations. The Anatomical Therapeutic Chemical (ATC) coding scheme of the World Health', 'Organization (WHO) will be used to group medications into relevant categories for these', 'tabulations. Separate data summaries of background medications will be provided.', '9.9.3.', 'Steering Committee', 'The conduct of this trial will be overseen by a steering committee (SC), presided over by the', 'coordinating Principal Investigator. The SC will serve in an advisory capacity to the Sponsor.', 'Operational details for the SC will be detailed in a separate SC charter.', 'Confidential and Proprietary', '50', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
50,page_51,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '10.', 'ADVERSE EVENTS', '10.1.', 'Monitoring, Recording and Reporting of Adverse Events', 'An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen', 'in a subject during the course of a study. It may be a new intercurrent illness, a worsening', ""concomitant illness, an injury, or any concomitant impairment of the subject's health, including"", 'laboratory test values (as specified by the criteria in Section 10.3), regardless of etiology. Any', 'worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-', 'existing condition) should be considered an AE. A diagnosis or syndrome should be recorded on', 'the AE/SAE page of the eCRF rather than the individual signs or symptoms of the diagnosis or', 'syndrome.', 'Abuse, withdrawal, sensitivity, or toxicity to an investigational product should be reported as an', 'AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be', 'reported on the overdose eCRF. (See Section 7.7 for definition of overdose.) Any sequela of an', 'accidental or intentional overdose of an investigational product should be reported as an AE on', 'the AE eCRF. If the sequela of an overdose is a serious adverse event (SAE), then the sequela', 'must be reported on the paper SAE report form and on the AE eCRF. The overdose resulting in', 'the SAE should be identified as the cause of the event on the paper SAE report form and eCRF,', 'but should not be reported as an SAE itself.', 'In the event of overdose, the subject should be monitored as appropriate and should receive', 'supportive measures as necessary. There is no known specific antidote for apremilast overdose.', 'Actual treatment should depend on the severity of the clinical situation and the judgment and', 'experience of the treating physician.', 'All subjects will be monitored for AEs during the study. Assessments may include monitoring of', ""any or all of the following parameters: the subject's clinical symptoms; laboratory, pathological,"", 'radiological, or surgical findings; physical examination findings; or findings from other tests', 'and/or procedures.', 'All AEs will be recorded by the Investigator from the time the subject signs informed consent', 'until 28 days after the last dose of IP as well all SAEs made known to the Investigator at any', 'time following the protocol-required reporting period or after end of study. All adverse events', '(serious/non-serious) will be recorded on the eCRF, the paper SAE report form (for SAEs) and in', ""the subject's source documents. All SAEs must be reported to Amgen Global Patient Safety"", ""within 24 hours of the Investigator's knowledge of the event by recording on the eCRF"", 'submitting the SAE information using the paper Serious Adverse Event Report Form by', 'facsimile/email directly to Amgen Global Patient Safety.', '10.2.', 'Evaluation of Adverse Events', 'A qualified Investigator will evaluate all adverse events as to:', '10.2.1.', 'Seriousness', 'A serious adverse event (SAE) is any AE occurring at any dose that:', 'Results in death;', 'Confidential and Proprietary', '51', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
51,page_52,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate', 'risk of death from the AE);', 'Requires inpatient hospitalization or prolongation of existing hospitalization', '(hospitalization is defined as an inpatient admission, regardless of length of stay);', 'Results in persistent or significant disability/incapacity (a substantial disruption of the', ""subject's ability to conduct normal life functions);"", 'Is a congenital anomaly/birth defect;', 'Constitutes an important medical event.', 'Important medical events are defined as those occurrences that may not be immediately', 'life-threatening or result in death, hospitalization, or disability, but may jeopardize the subject or', 'require medical or surgical intervention to prevent one of the other outcomes listed above.', 'Medical and scientific judgment should be exercised in deciding whether such an AE should be', 'considered serious.', 'Events not considered to be SAEs are hospitalizations for:', 'A standard procedure for protocol therapy administration. However, hospitalization', 'or prolonged hospitalization for a complication of therapy administration will be', 'reported as an SAE.', 'Routine treatment or monitoring of the studied indication not associated with any', 'deterioration in condition.', 'The administration of blood or platelet transfusion as routine treatment of studied', 'indication. However, hospitalization or prolonged hospitalization for a complication', 'of such transfusion remains a reportable SAE.', 'A procedure for protocol/disease-related investigations (eg, surgery, scans,', 'endoscopy, sampling for laboratory tests, bone marrow sampling). However,', 'hospitalization or prolonged hospitalization for a complication of such procedures', 'remains a reportable SAE.', 'Hospitalization or prolongation of hospitalization for technical, practical, or social', 'reasons, in absence of an AE.', 'A procedure that is planned (ie, planned prior to start of treatment on study); must be', 'documented in the source document and the eCRF. Hospitalization or prolonged', 'hospitalization for a complication from such a procedure remains a reportable SAE.', 'An elective treatment of, or an elective procedure for, a pre-existing condition', 'unrelated to the studied indication, that has not worsened from baseline.', 'Emergency outpatient treatment or observation that does not result in admission,', 'unless fulfilling other seriousness criteria above.', 'If an AE is considered serious, both the AE page/screen of the eCRF and the paper SAE Report', 'Form must be completed. All SAEs must be reported to Amgen Global Patient Safety within 24', ""hours of the investigator's knowledge of the event by submitting the SAE information using the"", 'Confidential and Proprietary', '52', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
52,page_53,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'paper Serious Adverse Event Report Form by facsimile/email directly to Amgen Global Patient', 'Safety.', 'For each SAE, the Investigator will provide information on severity, start and stop dates,', 'relationship to the IP, action taken regarding the IP, and outcome.', '10.2.2.', 'Severity / Intensity', 'For both AEs and SAEs, the Investigator must assess the severity/intensity of the event', 'according to the following grading scale:', 'Mild', 'Asymptomatic or mild symptoms; clinical or diagnostic observations only', 'Intervention not indicated', 'Activities of Daily Living (ADLs) minimally or not affected', 'No or minimal intervention/therapy may be required', 'Moderate', 'Symptom(s) cause moderate discomfort', 'Local or noninvasive intervention indicated', 'More than minimal interference with ADLs but able to carry out daily social and', 'functional activities.', 'Drug therapy may be required', 'Severe (could be non-serious or serious)', 'Symptoms causing severe discomfort/pain', 'Symptoms requiring medical/surgical attention/intervention', 'Interference with AEs including inability to perform daily social and functional', 'activities (eg, absenteeism and/or bed rest)', 'Drug therapy is required', 'The term ""severe"" is often used to describe the intensity of a specific event (as in mild, moderate,', 'or severe myocardial infarction); the event itself, however, may be of relatively minor medical', 'significance (such as severe headache). This criterion is not the same as ""serious"", which is', 'based on subject/event outcome or action criteria associated with events that pose a threat to a', ""subject's life or functioning."", 'Seriousness, not severity, serves as a guide for defining regulatory obligations.', '10.2.3.', 'Causality', 'The Investigator must determine the relationship between the administration of IP and the', 'occurrence of an AE/SAE as Not Suspected or Suspected as defined below:', 'Confidential and Proprietary', '53', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
53,page_54,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Not Suspected:', 'A causal relationship of the adverse event to IP administration is', 'unlikely or remote, or other medications, therapeutic interventions, or', 'underlying conditions provide a sufficient explanation for the observed', 'event.', 'Suspected:', 'There is a reasonable possibility that the administration of IP caused the', 'adverse event. ""Reasonable possibility\' means there is evidence to', 'suggest a causal relationship between the IP and the adverse event.', 'Causality should be assessed and provided for every AE/SAE based on currently available', 'information. Causality is to be reassessed and provided as additional information becomes', 'available.', 'If an event is assessed as suspected of being related to a comparator, ancillary, or additional IP', 'that has not been manufactured or provided by Amgen, please provide the name of the', 'manufacturer when reporting the event.', '10.2.4.', 'Duration', 'For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the', 'event.', '10.2.5.', 'Action Taken', 'The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable', '(eg, discontinuation, or interruption, or dose reduction of IP, as appropriate) and report if', 'concomitant and/or additional treatments were given for the event.', '10.2.6.', 'Outcome', 'The Investigator will report the outcome of the event for both AEs and SAEs.', ""All SAEs that have not resolved upon discontinuation of the subject's participation in the study"", 'must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to', 'the SAE).', '10.3.', 'Abnormal Laboratory Values', 'An abnormal laboratory value is considered to be an AE if the abnormality:', 'results in discontinuation from the study;', 'requires treatment, modification/interruption of IP dose, or any other therapeutic', 'intervention; or', 'is judged to be of significant clinical importance, eg, one that indicates a new disease', 'process and/or organ toxicity, or is an exacerbation or worsening of an existing', 'condition.', 'Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion', 'need to be documented as a serious adverse event.', 'Confidential and Proprietary', '54', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
54,page_55,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis', 'or syndrome should be recorded on the AE page/screen of the eCRF. If the abnormality was not', 'a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.', 'If possible, the laboratory abnormality should be recorded as a medical term and not simply as an', 'abnormal laboratory result (eg, record thrombocytopenia rather than decreased platelets).', '10.4.', 'Pregnancy', 'All pregnancies or suspected pregnancies occurring in either a female subject of childbearing', 'potential or partner of childbearing potential of a male subject are immediately reportable events.', '10.4.1.', 'Females of Childbearing Potential - Collection of Pregnancy Information', 'Pregnancies and suspected pregnancies (including elevated ß-hCG or positive pregnancy test in a', 'female subject of childbearing potential regardless of disease state) occurring while the subject is', ""on IP, or within 28 days of the subject's last dose of IP, are considered immediately reportable"", 'events. Investigational product is to be discontinued immediately. A female subject with', 'suspected pregnancy may resume IP after a confirmed negative pregnancy test and consultation', 'with the sponsor. The pregnancy, suspected pregnancy, or positive pregnancy test must be', 'reported to Amgen Global Patient Safety, or designee, immediately by email, facsimile, or', 'other appropriate method, using the Pregnancy Notification Form or approved equivalent form', '(refer to Appendix T). The Pregnancy Notification Form must be submitted to Amgen Global', ""Patient Safety within 24 hours of learning of a subject's pregnancy. (Note: Sites are not required"", 'to provide any information on the Pregnancy Notification Form that violates the country or', 'regions local privacy laws).', ""After obtaining the female subject's signed consent for release of pregnancy and infant health"", 'information, the investigator will collect pregnancy and infant health information and complete', 'the pregnancy questionnaire for any female subject who becomes pregnant while taking IP', ""through 28 days of the subject's last dose of IP. This information will be forwarded to Amgen"", 'Global Patient Safety. Generally, infant follow-up will be conducted 12 months after the birth of', 'the child (if applicable).', 'The female subject may be referred to an obstetrician-gynecologist or another appropriate', 'healthcare professional for further evaluation.', 'The Investigator will monitor the progress of the pregnancy of a female subject, and must notify', 'Amgen Global Patient Safety immediately about the outcome of the pregnancy (either normal or', 'abnormal outcome).', 'If the outcome of the pregnancy was abnormal (eg, spontaneous or therapeutic abortion), the', 'Investigator should report the abnormal outcome as an AE. If the abnormal outcome meets any', 'of the serious criteria, it must be reported as an SAE to Amgen Global Patient Safety by', ""facsimile, email or other appropriate method, within 24 hours of the investigator's knowledge of"", 'the event using the paper SAE Report Form.', 'All neonatal deaths that occur within 28 days of birth should be reported, without regard to', 'causality, as SAEs. In addition, any infant death after 28 days that the Investigator suspects is', 'related to the in-utero exposure to the IP should also be reported as an SAE to Amgen Global', 'Confidential and Proprietary', '55', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
55,page_56,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Patient Safety, by facsimile, email, or other appropriate method, within 24 hours of the', ""investigator's knowledge of the event using the paper SAE Report Form."", '10.4.2.', 'Male Subject With Partners Who Become Pregnant', 'In the event a male subject fathers a child during treatment, and for an additional 28 days after', 'discontinuing IP, the information will be recorded on the Pregnancy Notification Form (refer to', 'Appendix T). The form must be submitted to Amgen Global Patient Safety with 24 hours of the', ""investigator's/site awareness of the pregnancy (Note: Sites are not required to provide any"", 'information on the Pregnancy Notification Form that violates the country or regions local', 'privacy laws).', 'The investigator will attempt to obtain a signed consent for release of pregnancy and infant', 'health information directly from the pregnant female partner to obtain additional pregnancy', 'information.', ""After obtaining the female partner's signed consent for release of pregnancy and infant health"", 'information the investigator will collect pregnancy outcome and infant health information on the', 'pregnant partner and her baby and complete the pregnancy questionnaires. This information will', 'be forwarded to Amgen Global Patient Safety.', 'Generally, infant follow-up will be conducted up to 12 months after the birth of the child (if', 'applicable).', 'Any termination of the pregnancy will be reported to Amgen Global Patient Safety regardless of', 'fetal status (presence or absence of anomalies) or indication for procedure,', '10.4.3.', 'Collection of Lactation Information', 'Investigator will collect lactation information on any female subject who breastfeeds', 'while taking IP through 28 days post last dose of IP.', 'Information will be recorded on the Lactation Notification Form (refer to Appendix U)', 'and submitted by facsimile or email to Amgen Global Patient Safety within 24 hours of', ""the investigator's knowledge of event."", 'Study treatment will be discontinued if female subject breastfeeds during the study.', 'With the female subjects signed consent for release of mother and infant health', 'information, the investigator will collect mother and infant health information and', 'complete the lactation questionnaire on any female subject who breastfeeds while taking', 'IP through 28 days after discontinuing IP.', '10.5.', 'Reporting of Serious Adverse Events', 'Any AE that meets any serious criterion requires the completion of the relevant eCRFs and the', 'paper SAE report form. All SAEs must be reported to Amgen Global Patient Safety within 24', ""hours of the Investigator's knowledge of the event by sending the SAE data/information using"", 'the paper SAE report form. This instruction pertains to initial SAE reports as well as any', 'follow-up reports.', 'The Investigator is required to ensure that the data on these forms are accurate and consistent.', 'This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study', 'Confidential and Proprietary', '56', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
56,page_57,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '(from the time the subject signs informed consent until 28 days after the last dose of IP) and all', 'SAEs made known to the Investigator at any time following the protocol-required reporting', 'period or after end of study. . Serious adverse events occurring prior to treatment (after signing', 'the ICF) are to be collected/recorded/reported.', 'Where required by local legislation, the Investigator is responsible for informing the Institutional', 'Review Board/Ethics Committee (IRB/EC) of the SAE and providing them with all relevant', 'initial and follow-up information about the event. The Investigator must keep copies of all SAE', 'information on file including correspondence with Amgen and the IRB/EC.', 'Serious Adverse Event Reporting transmitted via paper Serious Adverse Event Report', 'Form:', 'Facsimile transmission of the Serious Adverse Event Report Form is the preferred', 'method to transmit this information. If facsimile is unavailable, the email method to', 'transmit this information is acceptable (refer to Appendix S).', 'In rare circumstances and in the absence of facsimile equipment, this form may be sent', 'via email, or notification by telephone is acceptable with a copy of the Serious Adverse', 'Event Report Form in English language sent by overnight mail or courier service.', 'Initial notification via telephone does not replace the need for the investigator to', 'complete and sign the Serious Adverse Event Report Form within the designated', 'reporting timeframes.', 'Once the study has ended, serious adverse events (regardless of causality) should be', 'reported to Amgen Global Patient Safety if the investigator becomes aware of them and', 'may use the paper Serious Adverse Event Report Form (refer to Appendix S).', '10.5.1.', 'Safety Queries', 'Queries pertaining to SAEs will be communicated/generated from Amgen Global Patient Safety', ""to the site via Amgen's safety query paper process or other appropriate method."", '10.6.', 'Expedited Reporting of Adverse Events', 'For the purpose of regulatory reporting, Amgen Global Patient Safety will determine the', ""expectedness of events suspected of being related to apremilast based on the Investigator's"", 'Brochure. For countries within the European Economic Area (EEA), Amgen or its authorized', 'representative will report in an expedited manner to Regulatory Authorities and Ethics', 'Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance', 'with Directive 2001/20/EC and the Detailed Guidance on collection, verification and', 'presentation of adverse reaction reports arising from clinical trials on investigational products for', 'human use (ENTR/CT3) and also in accordance with country-specific requirements.', 'Amgen or its authorized representative shall notify the Investigator of the following information:', 'Any AE suspected of being related to the use of IP in this study or in other studies', 'that is both serious and unexpected (ie, SUSAR).', 'Any finding from tests in laboratory animals that suggests a significant risk for', 'human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.', 'Confidential and Proprietary', '57', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
57,page_58,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of', 'these new serious and unexpected AE(s) or significant risks to subjects.', 'The Investigator must keep copies of all pertinent safety information on file including', 'correspondence with Amgen and the IRB/EC. (See Section 14.3 for record retention', 'information).', 'Amgen Global Patient Safety Contact Information (fax/email):', ""For Amgen Global Patient Safety contact information, please refer to your site's paper Serious"", 'Adverse Event Report Form, paper Pregnancy Notification Form and/or paper Lactation', 'Notification Form (Appendix S, Appendix T, Appendix U).', 'Confidential and Proprietary', '58', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
58,page_59,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '11.', 'DISCONTINUATIONS', '11.1.', 'Treatment Discontinuation', 'The following events are considered sufficient reasons for discontinuing a subject from the', 'investigational product(s):', 'Adverse event', 'Lack of efficacy', 'Non-compliance with investigational products', 'Withdrawal by subject', 'Death', 'Lost to follow-up', 'Protocol deviation', 'Pregnancy', 'Physician decision', 'Study terminated by sponsor', 'Other (to be specified on the eCRF)', 'Subjects have the right to withdraw from the study at any time and for any reason. The reason for', 'discontinuation should be recorded in the eCRF and in the source documents.', 'When a subject is discontinued from treatment, the Investigator should make every attempt', 'possible to have the subject evaluated at the Early Termination Visit within 4 days of the last', 'intake of investigational product.', 'The decision to discontinue a subject can be taken at any time and remains the responsibility of', 'the treating physician, which will not be delayed or refused by the sponsor. However, prior to', 'discontinuing a subject, the Investigator may contact the Medical Monitor or designee and', 'forward appropriate supporting documents for review and discussion, without identifying the', 'subject.', '11.2.', 'Study Discontinuation', 'The following events are considered sufficient reasons for discontinuing a subject from the', 'study:', 'Screen failure', 'Adverse event', 'Withdrawal by subject', 'Death', 'Lost to follow-up', 'Confidential and Proprietary', '59', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
59,page_60,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Protocol deviation', 'Pregnancy', 'Physician decision', 'Study terminated by Sponsor', 'Other (to be specified on the eCRF)', 'The reason for study discontinuation should be recorded in the eCRF and in the source', 'documents.', 'Confidential and Proprietary', '60', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
60,page_61,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '12.', 'EMERGENCY PROCEDURES', '12.1.', 'Emergency Contact', 'In emergency situations, the investigator should use their medical judgement to provide', 'appropriate medical care of clinical trial subjects. The Investigator may also contact the', 'responsible Clinical Research Physician/Medical Monitor or designee by telephone at the', 'number(s) listed on the Emergency Contact Information page of the protocol (after title page).', 'In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be', 'reached, the investigator may also contact the Amgen Medical Information number at 1-800-77-', 'AMGEN (1 800-772-6436). The representatives are responsible for obtaining your call-back', 'information and contacting the on-call Amgen/contract research organization Medical Monitor,', 'who will then contact you promptly.', '12.2.', 'Emergency Identification of Investigational Products', 'The blind must not be broken during the course of the study unless in the opinion of the', 'Investigator, it is absolutely necessary to safely treat the subject. If it is medically imperative to', 'know what IP the subject is receiving, IP should be temporarily discontinued if, in the opinion of', ""the Investigator, continuing IP can negatively affect the outcome of the subject's treatment."", 'The decision to break the blind in emergency situations remains the responsibility of the treating', 'physician, which will not be delayed or refused by the Sponsor. However, the Investigator may', 'contact the Medical Monitor prior to breaking the blind to discuss unblinding, mainly in the', 'interest of the subject.', 'The Investigator should ensure that the code is broken only in accordance with the protocol. The', 'Investigator should promptly notify the Medical Monitor of the emergency unblinding and the', 'reason for breaking the blind, which should be clearly documented by the Investigator in the', ""subject's source documentation."", 'Emergency unblinding should only be performed by the Investigator through the IRT by using an', 'emergency unblinding personal identification number (PIN), and the Investigator should contact', 'IRT for unblinded dose information.', 'Confidential and Proprietary', '61', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
61,page_62,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '13.', 'REGULATORY CONSIDERATIONS', '13.1.', 'Good Clinical Practice', 'The procedures set out in this study protocol pertaining to the conduct, evaluation, and', 'documentation of this study are designed to ensure that Amgen, its authorized representative, and', 'Investigator abide by Good Clinical Practice (GCP), as described in International Council for', 'Harmonisation (ICH) Guideline E6 and in accordance with the general ethical principles outlined', 'in the Declaration of Helsinki. The study will receive approval from an IRB/EC prior to', 'commencement. The Investigator will conduct all aspects of this study in accordance with', 'applicable national, state, and local laws of the pertinent regulatory authorities.', '13.2.', 'Investigator Responsibilities', 'Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in', 'the local regulations. Amgen staff or an authorized representative will evaluate and approve all', 'Investigators, who in turn will select their staff.', 'The Investigator should ensure that all persons assisting with the study are adequately informed', 'about the protocol, amendments, study treatments, as well as study-related duties and functions,', 'including obligations of confidentiality of Amgen information. The Investigator should maintain', 'a list of Sub-investigators and other appropriately qualified persons to whom he or she has', 'delegated significant study-related duties.', 'The Investigator is responsible for keeping a record of all subjects who sign an ICF and are', 'screened for entry into the study. Subjects who fail screening must have the reason(s) recorded in', ""the subject's source documents."", ""The Investigator, or a designated member of the Investigator's staff, must be available during"", 'monitoring visits to review data, resolve queries, and allow direct access to subject records (eg,', 'medical records, office charts, hospital charts, and study-related charts) for source data', 'verification. The Investigator must ensure timely and accurate completion of eCRFs and queries.', 'The information contained in the protocol and amendments (with the exception of the', 'information provided by Amgen on public registry websites) is considered Amgen confidential', 'information. Only information that is previously disclosed by Amgen on a public registry', 'website may be freely disclosed by the Investigator or its institution, or as outlined in the Clinical', 'Trial Agreement. Amgen protocol, amendment, and IB information is not to be made publicly', ""available (for example on the Investigator's or their institution's website) without express written"", ""approval from Amgen. Information proposed for posting on the Investigator's or their"", ""institution's website must be submitted to Amgen for review and approval, providing at least 5"", 'business days for review.', 'At the time results of this study are made available to the public, Amgen will provide', 'Investigators with a summary of the results that is written for the lay person. The Investigator is', 'responsible for sharing these results with the subject and/or their caregiver as agreed by the', 'subject.', 'Confidential and Proprietary', '62', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
62,page_63,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '13.3.', 'Subject Information and Informed Consent', ""The Investigator must obtain informed consent of a subject and/or a subject's legal representative"", 'prior to any study-related procedures. In addition to the main consent for the research study, the', 'subjects will be given the opportunity to consent to two optional sub-studies, ie, the', 'and, at selected sites only, photography.', ""Documentation that informed consent occurred prior to the study subject's entry into the study"", ""and of the informed consent process should be recorded in the study subject's source documents,"", 'including the date. The original ICF signed and dated by the study subject and by the person', ""consenting the study subject prior to the study subject's entry into the study, must be maintained"", ""in the Investigator's study files and a copy given to the study subject. In addition, if a protocol is"", 'amended and it impacts on the content of the informed consent, the ICF must be revised. Study', 'subjects participating in the study when the amended protocol is implemented must be re-', 'consented with the revised version of the ICF. The revised ICF signed and dated by the study', ""subject and by the person consenting the study subject must be maintained in the Investigator's"", 'study files and a copy given to the study subject.', 'Subjects have the right to withdraw from the study and sub-studies at any time and for any', 'reason. Subject information already obtained as part of the study and sub-studies will be retained', 'for analysis subject to applicable law. The Investigator shall ensure that all appropriate processes', 'regarding research ethics and subject consent have been followed in accordance with applicable', 'law and will notify Amgen in the event that any subject whose data is stored at or otherwise', 'processed by Amgen withdraws consent.', 'The subject data shall be key-coded (the direct identifiers will have been removed or replaced', 'with a subject code) prior to being transferred to the Sponsor or third parties. In particular,', 'appropriate protective mechanisms shall be implemented to ensure that photographs from the', 'sub-study do not contain any subject identifiers (for example, scars, tattoos, etc) when shared', 'with the Sponsor.', '13.4.', 'Confidentiality', ""Amgen affirms the subject's right to protection against invasion of privacy and to be in"", 'compliance with ICH and other local regulations (whichever is most stringent). Amgen requires', ""the Investigator to permit Amgen's representatives and, when necessary, representatives from"", 'regulatory authorities, to review and/or copy any medical records relevant to the study in', 'accordance with local laws.', 'Should direct access to medical records require a waiver or authorization separate from the', ""subject's signed ICF, it is the responsibility of the Investigator to obtain such permission in"", 'writing from the appropriate individual.', '13.5.', 'Protocol Amendments', 'Any amendment to this protocol must be approved by the Amgen Clinical Research', 'Physician/Medical Monitor. Amendments will be submitted to the IRB/EC for written approval.', 'Written approval must be obtained before implementation of the amended version occurs. The', 'written signed approval from the IRB/EC should specifically reference the Investigator name,', 'protocol number, study title, and amendment number(s) that is applicable. Amendments that are', 'Confidential and Proprietary', '63', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
63,page_64,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'administrative in nature do not require IRB/EC approval, but will be submitted to the IRB/EC for', 'information purposes.', '13.6.', 'Institutional Review Board/Independent Ethics Committee Review', 'and Approval', 'Before the start of the study, the study protocol, ICF, and any other appropriate documents will', 'be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their', 'dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is', 'sought. If applicable, the documents will also be submitted to the authorities in accordance with', 'local legal requirements.', 'IP can only be supplied to an Investigator by Amgen or its authorized representative after', 'documentation on all ethical and legal requirements for starting the study has been received by', 'Amgen or its authorized representative. This documentation must also include a list of the', 'members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose', 'the names, occupations and qualifications of the committee members, it should be asked to issue', 'a statement confirming that the composition of the committee is in accordance with GCP. For', 'example, the IRB General Assurance Number may be accepted as a substitute for this list.', 'Formal approval by the IRB/EC should mention the protocol title, number, amendment number', '(if applicable), study site (or region or area of jurisdiction, as applicable), and any other', 'documents reviewed. It must mention the date on which the decision was made and must be', 'officially signed by a committee member. Before the first subject is enrolled in the study, all', 'ethical and legal requirements must be met.', 'The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol', 'amendments in accordance with local legal requirements. Amendments must be evaluated to', 'determine whether formal approval must be sought and whether the ICF should also be revised.', 'The Investigator must keep a record of all communication with the IRB/EC and, if applicable,', 'between a Coordinating Investigator and the IRB/EC. This statement also applies to any', 'communication between the Investigator (or Coordinating Investigator, if applicable) and', 'regulatory authorities.', 'Any advertisements used to recruit subjects for the study must be reviewed by Amgen and the', 'IRB/EC prior to use.', '13.7.', 'Ongoing Information for Institutional Review Board/Ethics', 'Committee', 'If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:', 'Information on serious or unexpected adverse events as soon as possible;', 'Periodic reports on the progress of the study;', 'Deviations from the protocol or anything that may involve added risk to subjects.', 'Confidential and Proprietary', '64', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
64,page_65,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '13.8.', 'Termination of the Study', 'Amgen reserves the right to terminate this study at any time for reasonable medical or', 'administrative reasons. Any premature discontinuation will be appropriately documented', 'according to local requirements (eg, IRB/EC, regulatory authorities, etc).', 'In addition, the Investigator or Amgen has the right to discontinue a single site at any time during', 'the study for medical or administrative reasons such as:', 'Unsatisfactory enrollment;', 'GCP noncompliance;', 'Inaccurate or incomplete data collection;', 'Falsification of records;', 'Failure to adhere to the study protocol.', 'Confidential and Proprietary', '65', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
65,page_66,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '14.', 'DATA HANDLING AND RECORDKEEPING', '14.1.', 'Data/Documents', 'The Investigator must ensure that the records and documents pertaining to the conduct of the', 'study and the distribution of the investigational product are complete, accurate, filed, and', 'retained. Examples of source documents include: hospital records; clinic and office charts;', ""laboratory notes; memoranda; subject's diaries or evaluation checklists; dispensing records;"", 'recorded data from automated instruments; copies or transcriptions certified after verification as', 'being accurate copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and', 'the laboratories, as well as copies of eCRFs or CD-ROM.', '14.2.', 'Data Management', 'Data will be collected via eCRF and entered into the clinical database per Amgen standard', 'operating procedures (SOPs). These data will be electronically verified through use of', 'programmed edit checks specified by the clinical team. Discrepancies in the data will be brought', 'to the attention of the clinical team, and investigational site personnel, if necessary. Resolutions', 'to these issues will be reflected in the database. An audit trail within the system will track all', 'changes made to the data.', '14.3.', 'Record Retention', 'Essential documents must be retained by the Investigator for a minimum of 2 years after the last', 'approval of a marketing application in an ICH region and until there are no pending or', 'contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the', 'formal discontinuation of clinical development of the IP. The Investigator must retain these', 'documents for the time period described above or according to local laws or requirements,', 'whichever is longer. Essential documents include, but are not limited to, the following:', 'Signed ICFs for all subjects;', 'Subject identification code list, screening log (if applicable), and enrollment log;', 'Record of all communications between the Investigator and the IRB/EC;', 'Composition of the IRB/EC;', 'Record of all communications between the Investigator, Amgen, and their authorized', 'representative(s);', 'List of Sub-investigators and other appropriately qualified persons to whom the', 'Investigator has delegated significant study-related duties, together with their roles in', 'the study, curriculum vitae, and their signatures;', 'Copies of CRFs (if paper) and of documentation of corrections for all subjects;', 'IP accountability records;', 'Record of any body fluids or tissue samples retained;', 'All other source documents (subject records, hospital records, laboratory records,', 'etc.);', 'Confidential and Proprietary', '66', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
66,page_67,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'All other documents as listed in Section 8 of the ICH consolidated guideline on GCP', '(Essential Documents for the Conduct of a Clinical Trial).', 'The Investigator must notify Amgen if he/she wishes to assign the essential documents to', 'someone else, remove them to another location or is unable to retain them for a specified period.', 'The Investigator must obtain approval in writing from Amgen prior to destruction of any records.', 'If the Investigator is unable to meet this obligation, the Investigator must ask Amgen for', 'permission to make alternative arrangements. Details of these arrangements should be', 'documented.', 'All study documents should be made available if required by relevant health authorities.', 'Investigator/Institution should take measures to prevent accidental or premature destruction of', 'these documents.', 'Confidential and Proprietary', '67', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
67,page_68,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '15.', 'QUALITY CONTROL AND QUALITY ASSURANCE', 'All aspects of the study will be carefully monitored by Amgen or its authorized representative', 'for compliance with applicable government regulations with respect to current GCP and SOPs.', '15.1.', 'Study Monitoring and Source Data Verification', 'Amgen ensures that appropriate monitoring procedures are performed before, during, and after', 'the study. All aspects of the study are reviewed with the Investigator and the staff at a study', 'initiation visit and/or at an Investigator meeting. Prior to enrolling subjects into the study,', 'a', 'Amgen representative will review the protocol, eCRFs, procedures for obtaining informed', 'consent, record keeping, and reporting of AEs/SAEs with the Investigator. Monitoring will', 'include on-site visits with the Investigator and his/her staff as well as any appropriate', 'communications by mail, email, fax, or telephone. During monitoring visits, the facilities,', ""investigational product storage area, eCRFs, subject's source documents, and all other study"", 'documentation will be inspected/reviewed by the Amgen representative in accordance with the', 'Study Monitoring Plan.', 'Accuracy will be checked by performing source data verification that is a direct comparison of', 'the entries made onto the eCRFs against the appropriate source documentation. Any resulting', 'discrepancies will be reviewed with the Investigator and/or his/her staff. Any necessary', 'corrections will be made directly to the eCRFs or via queries by the Investigator and/or his/her', 'staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion', 'criteria and documentation of SAEs and their proper recording be verified. Additional', 'monitoring activities may be outlined in a study-specific monitoring plan.', '15.2.', 'Audits and Inspections', 'In addition to the routine monitoring procedures, a Quality, Compliance & Audit, Learning &', 'Performance unit exists within Amgen. Representatives of this unit will conduct audits of clinical', 'research activities in accordance with Amgen SOPs to evaluate compliance with Good Clinical', 'Practice guidelines and regulations.', 'The Investigator is required to permit direct access to the facilities where the study took place,', 'source documents, eCRFs, and applicable supporting records of study subject participation for', 'audits and inspections by IRB/IECs, regulatory authorities (eg, Food and Drug Administration', '[FDA], European Medicines Agency [EMA], Health Canada) and company authorized', 'representatives. The Investigator should make every effort to be available for the audits and/or', 'inspections. If the Investigator is contacted by any regulatory authority regarding an inspection,', 'he/she should contact Amgen immediately.', '15.3.', 'Product Complaint', 'A product complaint (PC) is any written, electronic, or oral communication that alleges', 'deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or', 'performance of a drug, combination product or device after they are released for distribution to', 'market or clinic by either Amgen or by distributors, and partners with whom Amgen', 'manufactures the material. This includes any drugs, devices, or combination products', 'provisioned and/or repackaged/modified by Amgen. Drugs or devices include investigational', 'Confidential and Proprietary', '68', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
68,page_69,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'product. Any product complaints associated with an investigational product, or non-', 'investigational products or devices supplied by Amgen are to be reported according to the', 'instructions provided in the Investigational Product Instruction Manual or equivalent.', 'If you become aware of a suspected PC, you are obligated to report the issue within 24 hours of', 'discovery or notification of the concern or irregularity. Amgen requires notification of any', 'concern or irregularity at any stage of the study.', '15.3.1.', 'How to Report a Product Complaint to Amgen', ""Complete Amgen's paper Clinical Product Complaint Intake Form and email the form to the"", 'following Amgen email address:', 'Clinical-Complaint-Intake@amgen.com', 'Confidential and Proprietary', '69', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
69,page_70,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '16.', 'PUBLICATIONS', 'As described in Section 13.2, all protocol- and amendment-related information, with the', 'exception of the information provided by Amgen on public registry websites, is considered', 'Amgen confidential information and is not to be used in any publications. Amgen protocol-', 'related information proposed for use in a publication must be submitted to Amgen for review and', 'approval, and should not be utilized in a publication without express written approval from', 'Amgen, or as described in the Clinical Trial Agreement.', 'Amgen will ensure Amgen-sponsored studies are considered for publication in the scientific', 'literature in a peer-reviewed journal, irrespective of the results. At a minimum, this applies to', 'results from all Phase 3 clinical studies, and any other study results of significant medical', 'importance. This also includes results relating to investigational medicines whose development', 'programs have been discontinued.', 'Study results may also be presented at one or more medical congresses, and may be used for', 'scientific exchange and teaching purposes. Additionally, this study and its results may be', 'submitted for inclusion in all appropriate health authority study registries, as well as publication', 'on health authority study registry websites, as required by local health authority regulations.', 'Eligibility for authorship, will be in alignment with ICMJE authorship criteria and be based on', 'several considerations, including, but not limited to, contribution to protocol development, study', 'recruitment, data quality, participation in data analysis, and contribution to abstract, presentation,', 'and/or publication development.', 'Confidential and Proprietary', '70', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
70,page_71,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '17.', 'REFERENCES', 'EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life.', 'Health Policy. 990;16(3):199-208.', 'Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the', 'assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res.', '2012;304(6):433-41.', 'Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for', 'routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6', 'Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica.', '1978;157(4):238-44.', 'Gottlieb AB. Psoriasis - Enhanced epidermal differentiation and reduced cell-mediated', 'inflammation are unexpected outcomes. Dis Manag Clin Outcome. 1998; 1 (6): 195-202.', 'Leonardi C, Sobell J, Sofen H, Krell J. Phase IV study to evaluate the safety and efficacy of', 'efalizumab for treatment of hand and foot plaque psoriasis. Poster presented at: 65th Annual', 'Meeting of the American Academy of Dermatology; 2007 Feb 2-6; Washington, DC.', 'Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature.', '2007;445(7130):866-73.', 'Merola JF, Bleakman AP, Gottlieb AB, Menter A, Naegeli AN, Bissonnette R, et al. The Static', ""Physician's Global Assessment of Genitalia: a clinical outcome measure for the severity of"", 'genital psoriasis. J Drugs Dermatol. 2017;16(8):793-9.', 'Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment', 'goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res.', '2011;303(1):1 -10.', 'Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The Worst Itch Numeric Rating', 'Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol.', '2015;54(6):715-22.', 'Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.', 'NHLBI Obesity Education Initiative. The practical guide: identification, evaluation, and', 'treatment of overweight and obesity in adults. [cited 2018 Apr 04]. Available from:', 'http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf.', 'Reilly Associates. Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI:PSO). 2012. [cited 2018 May 01]. Available from:', 'http://www.reillyassociates.net/WPAI_References3.html. Accessed May 01,.', 'Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.', 'J Am Acad Dermatol. 2003;49(2):206-12.', 'Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, et al. Product of', 'the Physician Global Assessment and body surface area: a simple static measure of psoriasis', 'severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931-7.', 'Confidential and Proprietary', '71', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
71,page_72,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '18.', 'APPENDICES', 'Appendix A: Table of Abbreviations', 'Table 4:', 'Abbreviations and Specialist Terms', 'Abbreviation or', 'Specialist Term', 'Explanation', 'ADL', 'Activities of daily living', 'AE', 'Adverse event', 'ALT', 'Alanine aminotransferase (SGPT)', 'ANCOVA', 'Analysis of covariance', 'APC', 'Antigen presenting cell', 'APR', 'Apremilast', 'AST', 'Aspartate aminotransferase (SGOT)', 'ATC', 'Anatomical Therapeutic Chemical', 'ß-hCG', 'Beta human chorionic gonadotropin', 'BID', 'Twice daily', 'BMI', 'Body mass index', 'BSA', 'Body surface area', 'BUN', 'Blood urea nitrogen', 'cAMP', 'Cyclic adenosine monophosphate', 'CBC', 'Complete blood count', 'CI', 'Confidence interval', 'CIN', 'Cervical intraepithelial neoplasia', 'CMH', 'Cochran-Mantel-Haenszel', 'CRO', 'Contract Research Organization', 'CLcr', 'Creatinine clearance', 'CRF', 'Case report form', 'DLQI', 'Dermatology Life Quality Index', 'DMARD', 'Disease-modifying antirheumatic drug', 'EC', 'Ethics Committee', 'eCRF', 'Electronic case report form', 'EEA', 'European Economic Area', 'eGFR', 'Estimated glomerular filtration rate', 'Confidential and Proprietary', '72', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
72,page_73,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 4:', 'Abbreviations and Specialist Terms (Continued)', 'Abbreviation or', 'Specialist Term', 'Explanation', 'EMA', 'European Medicines Agency', 'EOT', 'End of treatment', 'EQ-5D', 'European Quality of Life 5-Dimension Questionnaire', 'FCBP', 'Females of childbearing potential', 'FDA', 'Food and Drug Administration', 'GCP', 'Good Clinical Practice', 'GEE', 'Generalized estimating equations', 'GGT', 'Gamma-Glutamyl Transferase', 'HDPE', 'High-density polyethylene', 'IB', ""Investigator's Brochure"", 'ICF', 'Informed consent form', 'ICH', 'International Council for Harmonisation', 'IL', 'Interleukin', 'IP', 'Investigational product', 'IRB', 'Institutional Review Board', 'IRT', 'Interactive response technology', 'ITT', 'Intent to treat', 'IUD', 'Intrauterine device', 'LDH', 'Lactate Dehydrogenase', 'MCH', 'Mean Corpuscular Hemoglobin', 'MCHC', 'Mean Corpuscular Hemoglobin Concentration', 'MCV', 'Mean Corpuscular Volume', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MG', 'Milligrams', 'MI', 'Multiple imputation', 'MMRM', 'Mixed-Effect Model Repeated Measure', 'Modified sPGA-G', 'Modified Static Physicians Global Assessment of Genitalia', 'NAPSI', 'Nail Psoriasis Severity Index', 'NRS', 'Numeric Rating Scale', 'Confidential and Proprietary', '73', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
73,page_74,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 4:', 'Abbreviations and Specialist Terms (Continued)', 'Abbreviation or', 'Specialist Term', 'Explanation', 'PASI', 'Psoriasis Area Severity Index', 'PBI', 'Patient Benefit Index', 'PBQ', 'Patient Benefit Questionnaire', 'PDE', 'Phosphodiesterase', 'PDE4', 'Phosphodiesterase type 4', 'PNQ', 'Patient Needs Questionnaire', 'PP', 'Per protocol', 'PPPGA', 'Palmoplantar Psoriasis Physicians Global Assessment', 'PC', 'Product Complaint', 'PUVA', 'Psoralens and long-wave ultraviolet radiation', 'QOL', 'Quality of life', 'RBC', 'Red blood cell', 'SAE', 'Serious adverse event', 'SAP', 'Statistical analysis plan', 'SC', 'Steering committee', 'ScPGA', 'Scalp Physician Global Assessment', 'SGOT', 'Serum glutamic oxaloacetic transaminase', 'SGPT', 'Serum glutamic pyruvic transaminase', 'SOP', 'Standard operating procedure', 'sPGA', 'static Physicians Global Assessment', 'sPGA-G', 'static Physicians Global Assessment of Genitalia', 'SUSAR', 'Suspected unexpected serious adverse reaction', 'TNF', 'Tumor necrosis factor', 'UVB', 'Ultraviolet light B', 'VAS', 'Visual Analog Scale', 'WBC', 'White blood cell', 'WHO', 'World Health Organization', 'WPAI: PSO', 'Work Productivity and Activity Impairment Questionnaire: Psoriasis', 'Confidential and Proprietary', '74', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
74,page_75,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix B: The Dermatology Life Quality Index (DLQI)', 'The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE', 'LAST WEEK. Please check one box for each question.', '1.', 'Over the last week, how itchy, sore, painful or stinging has', '- Very much_Alot -', 'your skin been?', 'A little Not at all', '-', '-', '2.', 'Over the last week, how embarrassed or self conscious have', '- Very much A lot', '-', 'you been because of your skin?', 'A little Not at all', '-', '-', '3.', 'Over the last week, how much has your skin interfered with', '- Very much - A lot', 'you going shopping or looking after your home or garden?', 'A little Not at all', 'Not relevant', '-', '-', '4.', 'Over the last week, how much has your skin influenced the', 'Very much A lot', '-', '-', 'clothes you wear?', 'A little Not at all', 'Not relevant', '-', '-', '5.', 'Over the last week, how much has your skin affected any', 'Very much A lot', '-', '-', 'social or leisure activities?', 'A little Not at all', 'Not relevant', '-', '-', '6.', 'Over the last week, how much has your skin made it difficult', 'Very much A lot', '-', '-', 'for you to do any sport?', 'A little Not at all', 'Not relevant', '-', '-', '7.', 'Over the last week, has your skin prevented you from working', 'Yes No', 'Not relevant', '-', '-', '-', 'or studying?', 'If ""No"", over the last week how much has your skin been a', 'A lot - A little', '-', 'problem at work or studying?', 'Not at all', '-', 'Confidential and Proprietary', '75', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
75,page_76,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix B: The Dermatology Life Quality Index (DLQI) (Continued)', 'Please check one box for each question.', '8.', 'Over the last week, how much has your skin created problems', 'Very much A lot', '-', '-', 'with your partner or any of your close friends or relatives?', 'A little Not at all', 'Not relevant', '-', '-', '-', '9.', 'Over the last week, how much has your skin caused any', 'Very much A lot', '-', '-', 'sexual difficulties?', 'A little Not at all', 'Not relevant', '-', '-', '-', 'Over the last week, how much of a problem has the', '10.', 'Very much A lot', 'treatment for your skin been, for example, by making your', '-', '-', 'A little Not at all', 'Not relevant', 'home messy, or by taking up time?', '-', '-', '-', 'Source: Finlay, 1994.', 'Confidential and Proprietary', '76', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
76,page_77,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix C: Static Physicians Global Assessment (sPGA) Of Visible', 'Locations', 'The sPGA is the assessment by the Investigator of the overall disease severity at the time of', 'evaluation. In this study, sPGA is used to evaluate psoriasis only in visible locations, defined as', 'dorsal hand, face, neck and hairline.', 'Score', 'Category', 'Description', 'Plaque elevation = 0 (no elevation over normal skin)', '0', 'Clear', 'Scaling = 0 (no evidence of scaling)', 'Erythema = 0 (except for residual hyperpigmentation/', 'hypopigmentation)', 'Plaque elevation = (possible but difficult to ascertain whether', 'there is a slight elevation above normal skin)', '1', 'Almost Clear', 'Scaling = + (surface dryness with some desquamation)', 'Erythema = + (faint, diffuse pink or slight red coloration)', 'Plaque elevation = slight (slight but definite elevation, typically', 'edges are indistinct or sloped)', '2', 'Mild', 'Scaling = fine (fine scale partially or mostly covering lesions)', 'Erythema = mild (light red coloration)', 'Plaque elevation = marked (marked definite elevation with rough', 'or sloped edges)', '3', 'Moderate', 'Scaling = coarser (coarser scale covering most or all of the', 'lesions)', 'Erythema = moderate (definite red coloration)', 'Plaque elevation = marked (marked elevation typically with hard', 'or sharp edges)', '4', 'Severe', 'Scaling = coarser (coarse, non tenacious scale predominates', 'covering most or all of the lesions)', 'Erythema = severe (very bright red coloration)', 'Source: Walsh, 2013.', 'Confidential and Proprietary', '77', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
77,page_78,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix D: Scalp Physician Global Assessment (ScPGA)', 'Score', 'Category', 'Category Description', '0', 'Clear', 'Scalp Plaque Elevation = 0 (no elevation over normal skin)', 'Scalp Scaling = 0 (no evidence of scaling)', 'Scalp Erythema = 0 (except for residual', 'lyperpigmentation/hypopigmentation)', '1', 'Almost', 'Scalp Plaque Elevation = (possible but difficult to ascertain', 'Clear', 'whether there is a slight elevation above normal skin)', 'Scalp Scaling = (surface dryness with some desquamation)', 'Scalp Erythema = (faint, diffuse pink or slight red coloration)', '2', 'Mild', 'Scalp Plaque Elevation = slight (slight but definite elevation,', 'typically edges are indistinct or sloped)', 'Scalp Scaling = fine (fine scale partially or mostly covering lesions)', 'Scalp Erythema = mild (light red coloration)', '3', 'Moderate', 'Scalp Plaque Elevation = marked (marked definite elevation with', 'rough or sloped edges)', 'Scalp Scaling = coarser (coarser scale covering most or all of the', 'lesions)', 'Scalp Erythema = moderate (definite red coloration)', '4', 'Severe', 'Scalp Plaque Elevation = marked (marked elevation typically with', 'hard or sharp edges)', 'Scalp Scaling = coarser (coarse, non tenacious scale predominates', 'covering most or all of the lesions)', 'Scalp Erythema = severe (very bright red coloration)', 'Confidential and Proprietary', '78', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
78,page_79,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix E: Nail Psoriasis Severity Index (NAPSI)', 'The target thumb or finger nail which represents the worst nail', 'psoriasis is graded for nail matrix psoriasis and nail bed psoriasis.', 'The sum of these two scores is the total score for that nail.', 'Evaluation 1: Nail matrix. In each quadrant of', 'the nail, nail matrix psoriasis is evaluated by', 'presence of any of the nail matrix features', '(pitting, leukonychia red spots in the lunula,', 'crumbling):', 'Score for nail matrix psoriasis', '0 = none', '1 = present in 1/4 nail', '2 = present in 2/4 nail', '3 = present in 3/4 nail', '4 = present in 4/4 nail', 'Evaluation 2: Nail bed. Nail bed psoriasis is', 'evaluated by the presence of any of the nail bed', 'features (onycholysis, splinter hemorrhages,', 'subungual hyperkeratosis, ""oil drop"" (salmon', 'patch dyschroma):', 'Score for nail bed psoriasis', '0 = none', '1 = present in 1/4 nail', '2 = present in 2/4 nail', '3 = present in 3/4 nail', '4 = present in 4/4 nail', 'TOTAL FOR NAIL', '(0-8)', 'Source: Rich, 2003.', 'Confidential and Proprietary', '79', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
79,page_80,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix F: Modified Static Physicians Global Assessment of Genitalia', '(Modified sPGA-G)', 'The Modified Static Physician Global Assessment of Genitalia', 'Score¹', 'Category', 'Category Description²', 'Erythema: no erythema (except for residual', 'hyperpigmentation/ hypopigmentation)', '0', 'Clear', 'Plaque elevation: no elevation', 'Scaling: no scale', 'Erythema: faint, light pink erythema', '1', 'Almost Clear', 'Plaque elevation: elevation is very slight and difficult to', 'confirm', 'Scaling: some fine, white surface dryness', 'Erythema: mild, pink erythema', '2', 'Mild', 'Plaque elevation: slight elevation with sloped edges', 'Scaling: fine scale on some or most lesions', 'Erythema: moderate, red erythema', '3', 'Moderate', 'Plaque elevation: moderate elevation with definite edges', 'that are either sloped or rough', 'Scaling: coarse scale on most lesions', 'Erythema: severe, bright or deep red erythema', '4', 'Severe', 'Plaque elevation: substantial elevation, hard and sharp', 'edges', 'Scaling: coarse, non-adherent scale on most to all lesions', 'Adapted from source: Merola, 2017.', 'Confidential and Proprietary', '80', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
80,page_81,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix G: Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)', 'Scores and Descriptions', '0 Clear', 'No signs of plaque psoriasis on hands and/or feet', '1 Almost Clear', 'Just perceptible erythema and just perceptible scaling on the hands', 'and/or feet', '2 Mild', 'Light pink erythema with minimal scaling and with or without', 'pustules on hands and/or feet', '3 Moderate', 'Dull red, clearly distinguishable erythema with diffuse scaling, and', 'thickening of the skin, with or without fissures, and with or without', 'pustule formation on the hands and/or feet', '4 Severe', 'Deep/dark red erythema with clearly obvious and diffuse scaling and', 'thickening, and numerous fissures with or without pustule formation', 'on the hands and/or feet', 'Source: Leonardi, 2007.', 'Confidential and Proprietary', '81', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
81,page_82,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix H: Itch Numeric Rating Scale (NRS)', 'Please rate the itching severity due to your psoriasis by circling the number that best describes', 'your worst level of itching in the past 24 hours.', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '0 = No itching', '10 = Worst itch imaginable', 'Source: Naegeli, 2015.', 'Confidential and Proprietary', '82', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
82,page_83,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix I:', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', 'On average, how much skin discomfort/pain have you had because of your condition in the past', 'week?', 'Please use a vertical stroke', 'No pain at all', 'Worst possible pain', '0 mm', '100 mm', 'Please note: VAS above is not drawn to scale and is for illustrative purposes only.', 'Confidential and Proprietary', '83', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
83,page_84,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix J:', 'Psoriasis Area Severity Index (PASI)', '* Round all calculations to 1 decimal place.', 'STEP A. Please write in the appropriate number for rows 1 - 3 using the scale', 'below:', '0 = None 1 = Slight 2 = Moderate 3 = Severe 4 = Very Severe', 'UPPER', 'LOWER', 'HEAD', 'TRUNK', 'LIMBS', 'LIMBS', '1. Erythema', '2. Thickness', '3. Scaling', '4. TOTAL Each Column', 'STEP B. Enter the number of hands the psoriasis covers on each body area', 'UPPER', 'LOWER', 'HEAD', 'TRUNK', 'LIMBS', 'LIMBS', '5. Number of Hands', '6. Area (% of total BSA)', '10', '30', '20', '40', 'STEP C. Calculate % of involvement:', '7. % of each region involved [(Row 5 1/6 Row 6) x', '100*', '8. TOTAL BSA (sum of # of hands from row 5)', 'STEP D. Select Degree of Involvement using value in Row 7:', '0 = No involvement', '1 = <10%', '2 = 10 < 30%', '3 = 30 < 50%', '4 = 50 < 70%', '5 = 70 < 90%', '6 = 90 < 100%', '9. Degree of Involvement (0-6) of each region', 'STEP E. Calculate PASI (Row 4 x Row 6 x Row 9) / 100*', '10. PASI for each body region', '11. TOTAL PASI (sum of Row 10 subscores)', 'Source: Fredriksson, 1978.', 'Confidential and Proprietary', '84', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
84,page_85,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix K: Patient Needs Questionnaire (PNQ)', ""With the help of the following questions, we'd like to know how important the below mentioned"", 'goals are to you personally in the current treatment of your skin disease.', 'For each of the following statements, please mark how important this treatment goal is to you.', 'If a statement does not apply to you, e.g. because you do not have pain, please mark ""does not', 'apply to me"".', 'As a result of therapy, how important is it for you to', '1', 'be free of pain', 'O', 'O', 'O', 'O', 'O', 'O', '2', 'be free of itching', 'O', 'O', 'O', 'O', 'O', 'O', '3', 'no longer have burning sensations on your skin', 'O', 'O', 'O', 'O', 'O', 'O', '4', 'be healed of all skin defects', 'O', 'O', 'O', 'O', 'O', 'O', '5', 'be able to sleep better', 'O', 'O', 'O', 'O', 'O', 'O', '6', 'feel less depressed', 'O', 'O', 'O', 'O', 'O', 'O', '7', 'experience a greater enjoyment of life', 'O', 'O', 'O', 'O', 'O', 'O', '8', 'have no fear that the disease will become worse', 'O', 'O', 'o', 'O', 'O', 'O', '9', 'be able to lead a normal everyday life', 'O', 'O', 'O', 'O', 'O', 'O', '10', 'be more productive in everyday life', 'O', 'O', 'O', 'O', 'O', 'O', '11', 'be less of a burden to relatives and friends', 'O', 'O', 'O', 'o', 'O', 'O', '12', 'be able to engage in normal leisure activities', 'O', 'O', 'O', 'O', 'O', 'O', '13', 'be able to lead a normal working life', 'O', 'O', 'O', 'O', 'O', 'O', '14', 'be able to have more contact with other people', 'O', 'O', 'O', 'o', 'o', 'O', '15', 'be comfortable showing yourself more in public', 'O', 'O', 'O', 'O', 'O', 'O', '16', 'be less burdened in your partnership', 'O', 'O', 'O', 'O', 'O', 'O', '17', 'be able to have a normal sex life', 'o', 'o', 'o', 'O', 'o', 'o', '18', 'be less dependent on doctor and clinic visits', 'O', 'O', 'O', 'O', 'O', 'O', '19', 'need less time for daily treatment', 'O', 'O', 'O', 'O', 'O', 'O', '20', 'have fewer out-of-pocket treatment expenses', 'o', 'o', 'o', 'o', 'o', 'o', '21', 'have fewer side effects', 'O', 'O', 'O', 'O', 'O', 'O', '22', 'find a clear diagnosis and therapy', 'O', 'O', 'O', 'O', 'O', 'O', '23', 'have confidence in the therapy', 'O o o o o', 'O', '24', 'get better skin quickly', 'O', 'O', 'O', 'O', 'O', 'O', '25', 'regain control of the disease', 'O', 'O', 'O', 'O', 'O', 'O', 'Confidential and Proprietary', '85', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
85,page_86,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix L: Patient Benefit Questionnaire (PBQ)', 'At the start of the treatment, you indicated in a questionnaire how important various goals were', 'in the treatment of your skin disease.', 'Please mark each of the following statements according to the extent that these treatment goals', 'were achieved, thereby indicating if the treatment has benefitted you. If a statement did not', 'apply to you, e.g. because you had no pain, please mark ""did not apply to me"".', 'The current treatment has helped me to', '1', 'be free of pain', 'O', 'o', 'o', 'o', 'o', 'o', '2', 'be free of itching', 'O', 'O', 'O', 'O', 'O', 'O', '3', 'no longer have burning sensations on my skin', 'O', 'O', 'O', 'O', 'O', 'O', '4', 'be healed of all skin defects', 'o', 'o', 'o', 'o', 'O', 'o', '5', 'be able to sleep better', 'O', 'O', 'O', 'O', 'O', 'O', '6', 'feel less depressed', 'O', 'O', 'O', 'O', 'O', 'O', '7', 'experience a greater enjoyment of life', 'o', 'o', 'o', 'O', 'O', 'O', '8', 'have no fear that the disease will become worse', 'O', 'O', 'O', 'O', 'O', 'O', '9', 'be able to lead a normal everyday life', 'O', 'O', 'O', 'O', 'O', 'O', '10', 'be more productive in everyday life', 'o', 'O', 'O', 'o', 'o', 'o', '11', 'be less of a burden to relatives and friends', 'O', 'O', 'O', 'O', 'O', 'O', '12', 'be able to engage in normal leisure activities', 'O', 'O', 'O', 'O', 'O', 'O', '13', 'be able to lead a normal working life', 'O', 'O', 'o', 'o', 'o', 'o', '14', 'be able to have more contact with other people', 'O', 'O', 'O', 'O', 'O', 'O', '15', 'be comfortable showing myself more in public', 'O', 'O', 'O', 'O', 'O', 'O', '16', 'be less burdened in my partnership', 'o', 'O', 'o', 'o', 'o', 'o', '17', 'be able to have a normal sex life', 'O', 'O', 'o', 'O', 'O', 'O', '18', 'be less dependent on doctor and clinic visits', 'O', 'O', 'O', 'O', 'O', 'O', '19', 'need less time for daily treatment', 'o', 'O', 'o', 'o', 'o', 'o', '20', 'have fewer out-of-pocket treatment expenses', 'O', 'O', 'O', 'O', 'O', 'o', '21', 'have fewer side effects', 'O', 'O', 'O', 'O', 'O', 'O', '22', 'find a clear diagnosis and therapy', 'o', 'O', 'o', 'O', 'O', 'o', '23', 'have confidence in the therapy', 'O', 'O', 'O', 'O', 'O', 'O', '24', 'get better skin quickly', 'O', 'O', 'O', 'O', 'O', 'O', '25', 'regain control of the disease', 'o', 'o', 'o', 'o', 'o', 'o', 'Confidential and Proprietary', '86', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
86,page_87,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix M: European Quality of Life 5-Dimension Questionnaire (EQ-5D)', 'EQ-5D', 'Health Questionnaire', '(English version for the US)', '© 1998 EuroQol Group. EQ-5DTM is a trade mark of the EuroQol Group', 'Confidential and Proprietary', '87', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
87,page_88,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix M: European Quality of Life 5-Dimension Questionnaire (EQ-5D)', '(Continued)', 'By placing a checkmark in one box in each group below, please indicate which', 'statements best describe your own health state today.', 'Mobility', 'I have no problems in walking about', 'I have some problems in walking about', 'I am confined to bed', 'Self-Care', 'I have no problems with self-care', 'I have some problems washing or dressing myself', 'I am unable to wash or dress myself', 'Usual Activities (e.g. work, study, housework, family or', 'leisure activities)', 'I have no problems with performing my usual activities', 'I have some problems with performing my usual activities', 'I am unable to perform my usual activities', 'Pain/Discomfort', 'I have no pain or discomfort', 'I have moderate pain or discomfort', 'I have extreme pain or discomfort', 'Anxiety/Depression', 'I am not anxious or depressed', 'I am moderately anxious or depressed', 'I am extremely anxious or depressed', '2', '© 1998 EuroQol Group. EQ-5DTM is a trade mark of the EuroQol Group', 'Confidential and Proprietary', '88', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
88,page_89,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix M: European Quality of Life 5-Dimension Questionnaire (EQ-5D)', '(Continued)', 'Best', 'imaginable', 'health state', '100', 'To help people say how good or bad a health state is, we', 'have drawn a scale (rather like a thermometer) on which', 'the best state you can imagine is marked 100 and the', 'worst state you can imagine is marked 0.', '9', '0', 'We would like you to indicate on this scale how good', 'or bad your own health is today, in your opinion.', '8', '0', 'Please do this by drawing a line from the box below to', 'whichever point on the scale indicates how good or bad', 'your health state is today.', '7', '+0', '6', '0', 'Your own', 'health state', '5', '0', 'today', '4', '+0', '3', '0', '2', '0', '1', '0', '0', 'Worst', 'imaginable', '3', 'health state', '© 1998 EuroQol Group. EQ-5DTM is a trade mark of the EuroQol Group', 'Source: The EuroQol Group, 1990.', 'Confidential and Proprietary', '89', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
89,page_90,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix N: Work Productivity and Activity Impairment Questionnaire:', 'Psoriasis (WPAI: PSO)', 'WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE:', 'PSORIASIS (WPAI:PSO)', 'The following questions ask about the effect of your psoriasis on your ability to work and', 'perform regular activities. Please fill in the blanks or circle a number, as indicated.', '1) Are you currently employed (working for pay)?', 'NO', 'YES', 'If fon, check ""NO"" and skip to question 6', 'The next questions are about the past seven days, not including today.', '2) During the past seven days, how many hours did you miss from work because of problems', 'associated with your psoriasis? Include hours you missed on sick days, times you went in late,', 'left early, etc. because of psoriasis. Do not include time you missed to participate in this', 'study.', 'HOURS', '3) During the past seven days, how many hours did you miss from work because of any other', 'reason, such as vacation, holidays, time off to participate in this study?', 'HOURS', '4) During the past seven days, how many hours did you actually work?', 'HOURS (If ""0"", skip to question 6)', '5) During the past seven days, how much did psoriasis affect your productivity while you were', 'working? Think about days you were limited in the amount or kind of work you could do,', 'days you accomplished less than you would like, or days you could not do your work as', 'carefully as usual. If pporiasis affected your work only a little, choose a low number.', 'Choose a high number if psoriasis affected your work a great deal.', 'Psoriasis had no', 'Psoriasis completely', 'effect on my work', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'prevented me from', 'working', 'CIRCLE A NUMBER', '6) During the past seven days, how much did psoriasis affect your ability to do your regular', 'daily activities, other than work at a job? By regular activities, we mean the usual activities', 'you do, such as work around the house, shopping, child care, exercising, studying, etc. Think', 'about times you were limited in the amount or kind of activities you could do and times you', 'accomplished less than you would like. If psoriasis affected your activities only a little,', 'choose a low number. Choose a high number if pporiasis affected your activities a great', 'deal.', 'Psoriasis had no', 'Psoriasis completely', 'effect on my', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'prevented me from doing', 'daily activities', 'my daily activities', 'CIRCLE A NUMBER', 'WPAI:PSO (US English)', 'Source: Reilly, 2012.', 'Confidential and Proprietary', '90', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
90,page_91,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix O: Waist Circumference Measurement & Body Mass Index', 'Measuring Tape Position for Waist (Abdominal) Circumference', 'us', 'How to Measure Waist Circumference', ""1. Place a tape measure around subject's waist above the tip"", 'of hipbone.', '2. Ask the subject to exhale.', '3. Measure the waist after exhaling.', 'How to Measure Body Mass Index (BMI)', ""Body Mass Index (BMI) is a person's weight in kilograms divided by the square of"", ""height in meters. To estimate BMI, multiply the individual's weight (in pounds) by"", '703, then divide by the height (in inches) squared. This approximates BMI in', 'kilograms per meter squared (kg/m2).', 'BMI calculator can be found at:', 'https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/english_bmi_calculator/bmi_calcul', 'ator.html', 'Source: NHLBI Obesity Education Initiative.', 'Confidential and Proprietary', '91', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
91,page_92,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix P: Treatment Schema for Dose Titration at Baseline', 'Dose', 'Day 1', 'Day 2', 'Day 3', 'Day 4', 'Day 5', 'Group', 'AM', 'PM', 'AM', 'PM', 'AM', 'PM', 'AM', 'PM', 'AM', 'PM', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', 'Placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo +', 'placebo +', 'placebo +', 'placebo +', '(dummy', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '20 mg', '20 mg', '20 mg', '20 mg', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'titration)', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '30 mg', 'apremilast', 'placebo', 'apremilast', 'apremilast', 'apremilast', 'placebo', 'placebo +', 'placebo +', 'placebo +', 'placebo +', '+ 20 mg', '+ 20 mg', 'apremilast', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '20 mg', '20 mg', '20 mg', '20 mg', '(titration)', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'apremilast', 'apremilast', 'apremilast', 'apremilast', 'placebo', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'apremilast', 'Confidential and Proprietary', '92', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
92,page_93,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix Q: Treatment Schema for Dose Titration at Week 16', 'Dose', 'Day 1', 'Day 2', 'Day 3', 'Day 4', 'Day 5', 'Group', 'AM', 'PM', 'AM', 'PM', 'AM', 'PM', 'AM', 'PM', 'AM', 'PM', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', 'Placebo to', 'apremilast', 'placebo', 'apremilast', 'apremilast', 'apremilast', 'placebo', 'placebo +', 'placebo +', 'placebo +', 'placebo +', '30 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '20 mg', '20 mg', '20 mg', '20 mg', 'apremilast', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'apremilast', 'apremilast', 'apremilast', 'apremilast', 'placebo', '(titration)', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'apremilast', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '10 mg', '30 mg', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo +', 'placebo +', 'placebo +', 'placebo +', 'apremilast', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '+ 20 mg', '20 mg', '20 mg', '20 mg', '20 mg', '(dummy', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'placebo', 'titration)', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', '+ 30 mg', 'apremilast', 'apremilast', 'apremilast', 'apremilast', 'apremilast', 'apremilast', 'apremilast', 'apremilast', 'apremilast', 'apremilast', 'Confidential and Proprietary', '93', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
93,page_94,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix R: Titration Blister Card', '30mg BID Titration and Treatment Card (28 day +5 Extra)', 'MS', '1', 'FO', 'PW', '30p', '1', '10', '20p', '20p', '30p', '2', '10', '20p', '30p', '2', '10', '20p', '30p', '3', '10', 'fop', '20', '20p', '30p', '30p', '3', '4', '10p', '20', '30p', '4', 'Op', '20', '30p', '10p', '5', 'LOp', '20', '30p', '5', '20p', '30', '6', '30', '6', '30', '7', '30', '7', '30', '8', '30', '8', '30', '9', '30', '9', '30', '10', '30', '10', '30', '11', '30', '11', '30', '12', '30', '12', '30', '13', '30', '13', '30', '14', '30', '14', '30', '15', '30', '15', '30', '16', '30', '16', '30', '17', '30', '17', '30', '18', '30', '18', '30', '19', '30', '19', '30', '20', '30', '20', '30', '21', '30', '21', '30', '22', '30', '22', '30', '23', '30', '23', '30', '24', '30', '24', '30', '25', '30', '25', '30', '26', '30', '26', '30', '27', '30', '27', '30', '28', '30', '28', '30', '29', '30', '29', '30', '30', '30', '30', '30', '31', '30', '31', '30', '32', '30', '32', '30', '33', '30', '33', '30', 'Confidential and Proprietary', '94', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
94,page_95,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix S:', 'Sample Serious Adverse Event Form', 'AMGEN', 'Clinical Trial Serious Adverse Event Report - Phase 1-4', 'New', 'CC-10004-P BOR-020', 'Nouly Amgen Within 24 Hours of knowledge of the evenz', 'Apremilast', 'Follow-up', 'Reminder: Enzer the SAE Information Invo RAVE and then send the paper Serious', 'Adverse Evenz Reporz', ""Please refer 10 your site's Serious Adverse Evenz Report Form for Amgen Safezy's County Fax Number"", ""and If Fax Is unavallable, Amgen Safety's Country emall address."", '1. SITE INFORMATION', 'Site Number', 'Investigator', 'Country', 'Date of Report', 'Day', 'Month', 'Year', 'Reporter', 'Phone Number', 'Fex Number', '(', ')', '(', ')', '2. SUBJECT INFORMATION', 'Subject ID Number', 'Age et event breet', 'Sex', 'Race', 'If applicable, provide End of', 'Study date', 'F', 'M', '3.', 'SERIOUS ADVER SE EVENT - Information in this seczion must also be entered on the AE/Serious Adverse Evenz Summary CRF', 'Provide the date the Investigator became aware of this Serious Adverse Event Information: Day', 'Month', 'Year', 'Serious Adiverae Event Diagnonia or Syndrome', 'Chick', 'Relationship', 'Outcoma', 'Chackerly', 'If diagncais la unktown, enter Signa', 'Sertua', 'eart', 'la there e recconable possibility thet the event', 'of Event', '=', 'may have been caused by IPT', 'When Final Diagnonia la knowm, enter un', '=', '01 Rascived', 'aluca', 'If yes see section 10', 'Adverse Event', '02 Not', 'precedure', 'Data Sturied', 'Data Ended', 'belore', 'eg blapay', 'frat', '=', '03 Ratal', 'LES are , everé la enter the', 'dome: di', 'P', 'belad', 'Apremilact', '04', 'Cavas el Desth Chity a la not acceginbia,', 'as the a en', 'Dey Month Tae', 'Day Month Tear', 'Berlous 01 Fatal', '03 Required hospitalization', '06 Persistent or significant disabil ity incapacity', '07 Other medically', 'Criteria: 02 Immedialely life- threatening 04 Prolonged hospitalization', '08 Congenital anomaly. birth defect', 'important serious event', '4. HOSPITALIZATION', 'Date Admitted', 'Date Discharged', 'Dav', 'Month', 'Year', 'Dav', 'Month', 'Year', 'Was cubject hoopitalized or was a hoopitalization prolonged due to this', 'event?', 'No', 'Yes, r yes, please complete date(s):', '5. INVESTIGATIONAL PRODUCT (IP)', 'Initial Start Date', 'Prior to, or at time of Event', 'Action Taken with Product', 'Lot# and Berial #', 'Date of Dose', 'Dose', 'Route', 'Frequenay', 'un', 'Day', 'Month', 'Daty', 'Month', 'uz Perrarently', 'Year', 'Year', 'U3 Withheld', 'Apremilast', 'o', 'blinded', 'open label', 'o', 'FORM-015482 Cilical Trial SAE Report Phese 1-4 V10.0 Effective date: 23-April-2018', 'SAER Created: 02-April-2020', 'Page of 3', 'Confidential and Proprietary', '95', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
95,page_96,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix S:', 'Sample Serious Adverse Event Form (Continued)', 'AMGEN', 'Clinical Trial Serious Adverse Event Report - Phase 1-4', 'New', 'CC-10004-PSOR-020', 'Notify Amgen Within 24 Hours of knowledge of the event', 'Apremilast (Otezia)', 'Follow-up', 'Reminder: Enter the SAE information into RAVE and then send the paper Serious', 'Adverse Event Report', 'Site Number', 'Subject ID Number', '6. CONCOMITANT MEDICATIONS (eg. chemotherapy', 'Any Concomitant Medications?', 'No Yes, If yes please complete:', 'Start Date', 'Medication Name(e)', 'Stop Date', 'Co-suspect', 'Continuing', 'Treatment Med', 'Dose', 'Route', 'Freq.', 'Dey', 'Venth', 'Year', 'Day', 'Month', 'Year', 'Nor', 'Yen', 'No/', 'Yesr', 'No-', '7. RELEVANT MEDICAL HISTORY (include dates, allergies and any relevant prior therapy)', '8. RELEVANT LABORATORY VALUES (include baseline values) Any Relevant Laboratory values?', 'No', 'Yes, If yes, please complete:', 'Test', 'Unit', 'Date', 'Dap', 'Verth', 'Year', '9. OTHER RELEVANT TESTS (diagnostics and procedures)', 'Any Other Relevant tests?', 'No', 'Yes, If yes, please complete:', 'Date', 'Additional Tests', 'Results', 'Units', 'De Verth', 'FORM-015482 Clinical Trial SAE Report - Phase 1-4 V 10.0 Effective date: 23-April-2018', 'SAER Created 02-April-2020', 'Page 2 of 3', 'Confidential and Proprietary', '96', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
96,page_97,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix S:', 'Sample Serious Adverse Event Form (Continued)', 'AMGEN', 'Clinical Trial Serious Adverse Event Report - Phase 1-4', 'New', 'CC-10004-PSOR-020', 'Notify Amgen Within 24 Hours of knowledge of the event', 'Apremilast (Otezia)', 'Follow-up', 'Reminder: Enter the SAE information into RAVE and then send the paper Serious', 'Adverse Event Report', 'Site Number', 'Subject ID Number', '10. CASE DESCRIPTION (Provide narrative details of events listed in section 3) For each event in section 3, where relationship=Yes', 'please provide rationale.', 'Signature of Investigator or Designee', 'Title', 'Date', '/ confirm by signing this report that the information an this form, including', 'seriousness and cousality assessments, is being provided to Amgen by the', 'Investigator for this study, or by a Qualified Medical Peyson authorized by the', 'Investigator for this study.', 'FORM-015482 Clinical Trial SAE Report- - Phase 1-4 V 10.0 Effective date: 23-April-2018', 'SAER Created 02-April-2020', 'Page 3 of 3', 'Confidential and Proprietary', '97', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
97,page_98,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix T: Pregnancy Notification Form', 'Amgen Proprietary Confidential', 'AMGEN', 'Pregnancy Notification Form', ""Please refer to your site's Pregnancy Notification Form for Amgen Safety's Country Fax Number"", ""and if Fax is unavailable, Amgen Safety's Country email address."", '1. Case Administrative Information', 'Protocol/Study Number: CC-10004-PSOR-020', 'Study Design:', 'Interventional', 'Observational (If Observational:', 'Prospective', 'Retrospective)', '2. Contact Information', 'Investigator Name', 'Site #', 'Phone (', ')', 'Fax (', ')', 'Email', 'Institution', 'Address', '3. Subject Information', 'Subject ID #', 'Subject Gender:', 'Female', 'Male', 'Subject age (at onset):', '(in years)', '4. Amgen Product Exposure', 'Dose at time of', 'Amgen Product', 'Frequency', 'Route', 'Start Date', 'conception', 'mm', 'Add', 'Was the Amgen product (or study drug) discontinued?', 'Yes', 'No', 'If yes, provide product (or study drug) stop date: mm', '/dd', 'Did the subject withdraw from the study?', 'Yes', 'No', '5. Pregnancy Information', ""Pregnant female's last menstrual period (LMP)"", 'mm', '/ dd', 'Unknown', 'N/A', 'Estimated date of delivery mm', '/ dd', '/', 'If N/A. date of termination (actual or planned) mm', '/ dd', '/', 'Has the pregnant female already delivered?', 'Yes', 'No', 'Unknown', 'N/A', 'If yes, provide date of delivery. mm', 'dd', '/', 'Was the infant healthy?', 'Yes', 'No', 'Unknown', 'N/A', 'If any Adverse Event was experienced by the infant, provide brief details:', 'Form Completed by:', 'Print Name:', 'Title:', 'Signature:', 'Date:', 'FORM-115199', 'Version 1.0', 'Effective Date: 24-Sept-2018', 'Confidential and Proprietary', '98', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
98,page_99,"['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix U: Lactation Notification Form', 'Amgen Proprietary Confidential', 'AMGEN', 'Lactation Notification Form', ""Please refer to your site's Lactation Notification Form for Amgen Safety's Country Fax Number"", ""and if Fax is unavailable, Amgen Safety's Country email address."", '1. Case Administrative Information', 'Protocol/Study Number: CC-10004-PSOR-020 (Aptemuliaat/Otezia)', 'study Design:', 'Interventional', 'Observational (If Observational:', 'Prospective', 'Retrospective)', '2. Contact Information', 'Investigator Name', 'Site #', 'Phone (', ')', 'Fax (', ')', 'Emall', 'Institution', 'Address', '3. Subject Information', 'subject ID #', 'Subject age (at onset):', '(in years)', '4. Amgen Product Exposure', 'Dose at time of', 'Amgen Product', 'Frequency', 'Route', 'start Date', 'breast feeding', 'mm', '/dd', 'how', 'Was the Amgen product (or study drug) discontinued?', 'Yes', 'No', 'If yes, provide product (or study drug) stop date: mm', '/dd', 'Did the subject withdraw from the study?', 'Yes', 'No', '5. Breast Feeding Information', 'Did the mother breastfeed or provide the infant with pumped breast milk while actively taking an Amgen product? Yes', 'No', 'If No, provide stop date: mm', '/dd', 'Infant date of birth: mm', '(dd', '200%', 'Infant gender:', 'Female', 'Male', 'Is the infant healthy?', 'Yes', 'No', 'Unknown', 'N/A', 'If any Adverse Event was experienced by the mother or the infant, provide brief details:', 'Form Completed by', 'Print Name:', 'Title:', 'Signature:', 'Date:', 'FORM-115201', 'Version 1.0', 'Effective Date: 24-Sept-2018', 'Confidential and Proprietary', '99', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']"
99,page_100,"['Celgene', 'Celgene Signing Page', 'This is a representation of an electronic record that was signed electronically in Livelink.', 'This page is the manifestation of the electronic signature(s) used in compliance with', 'the organizations electronic signature policies and procedures.', 'UserName:', 'Title: Vice President and Head of Immunology & Fibrosis Clinical Develo', 'Date: Tuesday, 05 May 2020, 08:23 AM Eastern Daylight Time', 'Meaning: Approved, no changes necessary.', 'EDMS Doc. Number: 24684941 - 22835610']"
100,page_101,"['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Amgen Inc.', '- SUMMARY OF CHANGES- -', 'A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-', 'BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT', 'OF APREMILAST (CC-10004) ON QUALITY OF LIFE,', 'EFFICACY, AND SAFETY IN SUBJECTS WITH', 'MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED', 'QUALITY OF LIFE', 'AMENDMENT NO. 3', 'INVESTIGATIONAL PRODUCT (IP):', 'Apremilast', 'PROTOCOL NUMBER:', 'CC-10004-PSOR-020', 'ORIGINAL DATE:', '26 SEP 2018', 'AMENDMENT No. 1 DATE:', '17 JAN 2019', 'AMENDMENT No. 2 DATE:', '01 NOV 2019', 'AMENDMENT No. 3 DATE:', '01 MAY 2020', 'EudraCT NUMBER:', '2018-002850-58', 'IND NUMBER:', '070270', 'NTC NUMBER:', 'NCT03774875', 'Contact Information:', 'Name:', ', MD', 'Title:', 'Senior Director, Global Development', 'Address:', 'Amgen Inc,', 'Amgen Center Dr, Thousand Oaks, CA 91320', 'USA', 'Phone:', 'E-mail:', 'Note: Only call Amgen Medical Information, if you are not able to reach the Clinical Research', 'Physician(s) or Medical Monitor or designee for emergency calls.', 'Amgen Medical Information: -800-77-AMGEN (1-800-772-6436)', 'CONFIDENTIALITY NOTICE', 'This document contains confidential information of Amgen. This document must not be disclosed to', 'anyone other than the site study staff and members of the institutional review board/independent ethics', 'committee/institutional scientific review board or equivalent. The information in this document cannot', 'be used for any purpose other than the evaluation or conduct of the clinical investigation without the', 'prior written consent of Amgen. If you have questions regarding how this document may be used or', 'shared, call the Amgen Medical Information number: 1- - 800-77-AMGEN', 'Confidential and Proprietary', '1', 'CC-10004-PSOR-020 Amendment # 3 Final: 01 May 2020', 'EDMS Doc. Number: 24684941 - 23306134']"
101,page_102,"['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Amgen Inc.', 'CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE', '{See appended electronic signature page)', 'Signature of Celgene Therapeutic Area Head', 'dd mmm yyyy', 'Vice President and Head of Immunology &Fibrosis Clinical', 'Development', 'Printed Name of Celgene Therapeutic Area Head and Title', 'By my signature, I indicate I have reviewed this summary of changes and find its', 'content to be acceptable.', 'NOTE: Signed by Celgene based on Approval from Amgen Therapeutic Head', 'Confidential and Proprietary', '2', 'CC-10004-PSOR-020 Amendment # 3 Final: 01 May 2020', 'EDMS Doc. Number: 24684941 - 23306134']"
102,page_103,"['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Amgen Inc.', 'JUSTIFICATION FOR AMENDMENT', 'The purpose of this amendment is to update the change in Sponsor, as well as key contact and', 'emergency information, and to update safety reporting and product complaints to align with', 'Amgen processes.', 'Significant changes included in this amendment are summarized below:', 'All references to ""Celgene Corporation"" were removed and replaced with ""Amgen Inc""', 'and ""Celgene"" changed to ""Amgen"" throughout the protocol.', 'Cover Pages were updated with Amgen contact information', 'Section 6 Procedures was updated to align with Amgen Global Drug Safety processes', 'Section 10 Monitoring and Reporting of Adverse Events was updated to align with', 'Amgen Global Drug Safety processes.', 'Section 10.4 Pregnancy was modified according to the Amgen Global Drug Safety', 'process:', 'Collection of Pregnancy Information and Infant Health Information', 'Collection of information: Male Subjects with Partners Who Become Pregnant', 'Collection of Lactation Information', 'Section 10.5 Reporting of Serious Adverse Events was updated to include instructions for', 'paper reporting of SAEs', 'Section 12.1 Emergency Contact was updated with Amgen emergency contact', 'information.', 'Section 15.3 Product Complaint Section was modified according to the Amgen product', 'complaint reporting process', 'The amendment also includes addition of forms, minor clarifications and corrections to', 'align with Amgen processes:', 'Section 7.5 Investigational Product Accountability', 'Section 15.2 Audits and Inspections', 'Section 16 Publications', 'Appendix S Sample Serious Adverse Event Form was added', 'Appendix T Pregnancy Notification Form was added', 'Appendix U Lactation Notification Form was added', 'Confidential and Proprietary', '3', 'CC-10004-PSOR-020 Amendment # 3 Final: 01 May 2020', 'EDMS Doc. Number: 24684941 - 23306134']"
103,page_104,"['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Celgene International II SARL', '- SUMMARY OF CHANGES- -', 'AMENDMENT NO. 2', 'A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-', 'BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT', 'OF APREMILAST (CC-10004) ON QUALITY OF LIFE,', 'EFFICACY, AND SAFETY IN SUBJECTS WITH', 'MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED', 'QUALITY OF LIFE', 'INVESTIGATIONAL PRODUCT (IP):', 'Apremilast (CC-10004)', 'PROTOCOL NUMBER:', 'CC-10004-PSOR-020', 'ORIGINAL DATE:', '26-SEP-2018', 'AMENDMENT No. 1 DATE:', '17-JAN-2019', 'AMENDMENT No. 2 DATE:', '01 NOV 2019', 'EudraCT NUMBER:', '2018-002850-58', 'IND NUMBER:', '070270', 'Contact Information:', 'Name:', ', MD', 'Title:', 'Senior Medical Director, Global Medical Affairs, Dermatology', 'Address:', 'Celgene Corporation', '86 Morris Avenue', 'Summit, NJ 07901', 'Phone:', 'E-mail:', 'CONFIDENTIAL', 'This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by', 'you, your staff, and ethics committee/institutional review board. The information contained in this', 'document is regarded as confidential and, except to the extent necessary to obtain informed consent,', 'may not be disclosed to another party unless such disclosure is required by law or regulations.', 'Persons to whom the information is disclosed must be informed that the information is confidential', 'and may not be further disclosed by them.', 'Confidential and Proprietary', '1', 'CC-10004-PSOR-020 Amendment 2 Final: 01 Nov 2019', 'EDMS Doc. Number: 24238115 - 23306134']"
104,page_105,"['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Celgene International II SARL', 'CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE', '{See appended electronic signature page)', 'Signature of Celgene Therapeutic Area Head', 'dd mmm yyyy', ', PhD, Vice President, Medical Affairs Inflammation and Immunology,', 'Rheumatology and Dermatology', 'By my signature, I indicate I have reviewed this summary of changes and find its', 'content to be acceptable.', 'Confidential and Proprietary', '2', 'CC-10004-PSOR-02( Amendment 2 Final: 01 Nov 2019', 'EDMS Doc. Number:24238115 -23306134 -']"
105,page_106,"['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Celgene International II SARL', '1.', 'JUSTIFICATION FOR AMENDMENT', 'Significant changes included in this amendment are summarized below:', '-', 'Randomization to each of the 5 manifestations of plaque psoriasis', 'The primary purpose of this protocol amendment is to remove the requirement for equal block-', 'randomization to each of the 5 manifestations of plaque psoriasis. The basis for this change', 'stems from the different enrollment rates in the 5 manifestation groups with a corresponding risk', 'of missing the sample size required for the primary endpoint. This change does not impact the', 'study endpoints.', 'Revised sections: Protocol Summary, 3.1 Study Design, 4.3 Exclusion Criteria, 7.3 Method of', 'Treatment Assignment.', '- Updated modalities for reporting of serious adverse events (SAEs) and pregnancy', 'Reporting modalities were updated to reflect the use of an electronic case report form (eCRF)-', 'based system for reporting of SAEs and clarified expectations for pregnancy reporting.', 'Revised sections: 6.5.8 Adverse Events, 10.4.1 Females of Childbearing Potential, 10.5', 'Reporting of Serious Adverse Events (with 10.5.1 deleted) and 10.6 Expedited Reporting of', 'Adverse Events', 'The Amendment also includes several other minor clarifications and corrections:', '- Medical Monitor and Celgene Therapeutic Area Head information was updated.', '-', 'In Section 2, Table 2 Safety endpoints were combined with Secondary endpoints;', 'Exploratory endpoint on', '-', 'In Section 4.3, Exclusion Criteria # 3 clarified to refer specifically to arthritis requiring', 'disease-modifying antirheumatic drug.', '- In Section 5, Table 3, Screening visit window: clarified to be -35 to 0 days.', '-', 'In Section 6.5.4, Psychiatric Evaluation, language aligned with Risk Benefit Assessment', 'and Investigator Brochure for patients with identified attempted suicide.', '-', 'Where appropriate, references to CRF have been revised to eCRF.', 'Confidential and Proprietary', '3', 'CC-10004-PSOR-02( Amendment 2 Final: 01 Nov 2019', 'EDMS Doc. Number:24238115 -23306134 -']"
106,page_107,"['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Celgene International II SARL', '- SUMMARY OF CHANGES -', 'AMENDMENT NO 1.', 'A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-', 'BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT', 'OF APREMILAST (CC-10004) ON QUALITY OF LIFE,', 'EFFICACY, AND SAFETY IN SUBJECTS WITH', 'MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED', 'QUALITY OF LIFE', 'INVESTIGATIONAL PRODUCT (IP):', 'Apremilast (CC-10004)', 'PROTOCOL NUMBER:', 'CC-10004-PSOR-020', 'ORIGINAL DATE:', '26 SEP 2018', 'AMENDMENT No. 1 DATE:', '17 JAN 2019', 'EudraCT NUMBER:', '2018-002850-58', 'IND NUMBER:', '070270', 'Contact Information:', 'Name:', ', MD', 'Title:', 'Medical Director', 'Address:', 'Celgene Corporation', '86 Morris Avenue', 'Summit, NJ 07901', 'Phone:', 'E-mail:', 'CONFIDENTIAL', 'This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by you, your', 'staff, and ethics committee/institutional review board. The information contained in this document is regarded as', 'confidential and, except to the extent necessary to obtain informed consent, may not be disclosed to another party', 'unless such disclosure is required by law or regulations. Persons to whom the information is disclosed must be', 'informed that the information is confidential and may not be further disclosed by them.', 'Confidential and Proprietary', '1', 'CC-10004-PSOR-02( Amendment 1 Final: 17 Jan 2019', 'EDMS Doc. Number: 23372629 - 23306134']"
107,page_108,"['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Celgene International II SARL', 'CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE', '{See appended electronic signature page)', 'Signature of Celgene Therapeutic Area Head', 'dd mmm yyyy', ',', 'MD, Corporate Vice President, Global Medical Affairs', 'Inflammation and Immunology', 'By my signature, I indicate I have reviewed this summary of changes and find its', 'content to be acceptable.', 'Confidential and Proprietary', '2', 'CC-10004-PSOR-020 Amendment 1 Final: 17 Jan 2019', 'EDMS Doc. Number:23372629 -23306134 -']"
108,page_109,"['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Celgene International II SARL', '1.', 'JUSTIFICATION FOR AMENDMENT', 'Significant changes included in this amendment are summarized below:', 'In the Protocol Summary; Overview of Key Safety Assessments, Physical examinations', 'was changed to Body weight and waist circumference as body weight and waist', 'circumference is done throughout the study and Physical examination is done at', 'Screening.', 'In Section 2, Table 1; removed text, ""data from the exploratory objectives may not be', 'included in the clinical study report"", as the clinical study report will include data from', 'exploratory analyses.', 'In Section 2, Table 2; added Safety Endpoints, based on Health Authority', 'recommendations.', 'In Section 4.2; clarified Inclusion Criteria 4, 9 and 11, to align to approved label', 'indication for psoriasis and address Health Authority recommendations.', 'In Section 4.3; deleted Exclusion Criteria 1, clarified Exclusion Criteria 6 and added', 'Exclusion Criteria 7, 8, 16 and 17 to align to approved label and address Health Authority', 'recommendations. Exclusion Criteria # 18 was added to address exclusions for', 'completion of randomization blocks for the disease manifestations noted in Inclusion', 'Criteria #7.', 'Modified Section 5 Table of Events to include additional Vital signs and body weight', 'measures, based on Health Authority recommendations.', 'Modified Section 6.1, to clarify demography data collection and clinical laboratory', 'evaluation, based on Health Authority recommendations.', 'Provided clarification in Section 6.2 for Efficacy assessment, as investigators may asses', 'efficacy and safety at any unscheduled visit, following country guidelines.', 'Modified Sections 6.4.14 and 6.4.15 to clarify that data from', 'and photography will be included in the clinical study report.', 'Added Section 6.5 specifying safety assessments and address Health Authority', 'recommendations.', 'Modified Section 8.1 to clarify data collection of permitted concomitant medication.', 'Added Section 8.2, ""Concomitant Medications Not Recommended"", based on Health', 'Authority recommendations.', 'Modified Sections 9.6.3 and 9.6.4 to include data from exploratory objectives in study', 'report, based on Health Authority recommendations.', 'Provided clarification in Section 9.7 Safety Analysis, based on Health Authority', 'recommendations.', 'Modified Sections 10.1 and 10.5 to clarify AE and SAE reporting will be done', 'electronically through database.', 'Clarified Section 11.1, Treatment Discontinuation, based on Health Authority', 'recommendations.', 'Confidential and Proprietary', '3', 'CC-10004-PSOR-020 Amendment 1 Final: 17 Jan 2019', 'EDMS Doc. Number: 23372629 - 23306134']"
